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Technological innovations have produced large multi-modal datasets that range 
in multiplatform genomic data, pathway data, proteomic data, imaging data and 
clinical data. Integrative analysis of such data sets have potentiality in 
revealing important biological and clinical insights into complex diseases like 
cancer. This dissertation focuses on Bayesian methodology establishment in 
integrative analysis of radiogenomics and pathway driver detection applied in 
cancer applications. We initially present Radio-iBAG that utilizes Bayesian 
approaches in analyzing radiological imaging and multi-platform genomic data, 
which we establish a multi-scale Bayesian hierarchical model that 
simultaneously identifies genomic and radiomic, i.e., radiology-based imaging 
markers, along with the latent associations between these two modalities, and 
to detect the overall prognostic relevance of the combined markers. Our method 
is motivated by and applied to The Cancer Genome Atlas glioblastoma 
multiforme data set, wherein it identifies important magnetic resonance 
imaging features and the associated genomic platforms that are also 
significantly related with patient survival times. For another aspect of 
integrative analysis, we then present pathDrive that aims to detect key genetic 
and epigenetic upstream drivers that influence pathway activity. The method is 
applied into colorectal cancer incorporated with its four molecular subtypes. 
For each of the pathways that significantly differentiates subgroups, we detect 
important genomic drivers that can be viewed as “switches” for the pathway 
activity. To extend the analysis, finally, we develop proteomic based pathway 
driver analysis for multiple cancer types wherein we simultaneously detect 
genomic upstream factors that influence a specific pathway for each cancer 
type within the cancer group. With Bayesian hierarchical model, we detect 
signals borrowing strength from common cancer type to rare cancer type, and 
simultaneously estimate their selection similarity. Through simulation study, 
our method is demonstrated in providing many advantages, including increased 
power and lower false discovery rates. We then apply the method into the 
analysis of multiple cancer groups, wherein we detect key genomic upstream 
drivers with proper biological interpretation. The overall framework and 
methodologies established in this dissertation illustrate further investigation in 
the field of integrative analysis of omics data, provide more comprehensive 
insight into biological mechanisms and processes, cancer development and 
progression. 
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Chapter 1
Introduction
High-throughput technologies increasingly enable the advent of probing multiple
biological layers in parallel, which involves quantitative monitor of multiple profiles
ranging from genome, transcriptome, epigenome, proteome to phenome profiling [39].
This comprehensive assessment of a molecular set is termed “omics”, with further
extension as “multi-omics” referring to biological analysis methods where the data
sets contain multiple “omes”. In order to achieve more comprehensive investigation
into biological processes, integrative analyses that utilize information across these
multiple data modalities have become a promising biological research area. The
topic of integrative analysis of multi-omics data faces several main challenges: the
complicated biological systems and processes, limitation in measuring technologies,
high dimensionality with large number of variables and relatively lower sample size.
To address the challenges, di↵erent types of integrative approaches applied to a wide
range of biological problems have been established.
From methodological perspective, to classify the existing methods, the typical crite-
rion is whether it belongs to bayesian (BY) approach [12] [99] where it incorporates
prior information into the modeling scheme. From application perspective, one type
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of research involves the study in molecular biological regulatory mechanisms, which
unravel complex cellular biological processes. This type of studies has been shown
to have promising advantages, such as higher statistical power and decreased false
discovery rates as Wang et. al., 2013 [112] illustrates. Besides integrative analysis at
molecular level, another research area is the study of Radiomics data which refers
to the high-throughput extraction of numbers of image features from images [58].
Furthermore, a recent research area termed “radiogenomics” which creates a link
between molecular properties with imaging phenotypes has drawn great attention of
researchers. The research field incorporates novel approaches digging into the hid-
den associations between gene expression patterns with radiomic phenotypes [94] [45].
Another integrative analyzing application area is related with Network Biology
which has become a nascent and burgeoning subfield of systems biology that involves
the discovery and characterization of molecular interactions underlying complex
diseases, including cancer. One aspect of this field is the study of molecular pathways
that have been discovered and curated by systems biologists. Di↵erent methods have
been developed to accurately measure pathway activity, such as Gene set enrichment
analysis (GSEA) [104] and pathway level gene expression analysis using singular
value decomposition [109], which all alleviate the complexity in analyzing large
amount of individual genes or proteins and simultaneously provide clearer picture of
biological functional processes, components or structures [54].
Integrative analysis for one particular cancer type has been widely applied such
as Hu et al., 2017 [45] which conducts radiogenomic analysis into the investigation
of genetic heterogeneity in glioblastoma. Current integrative analysis has extended
to the analysis of pan-cancer which initiatively targets to examine the similarities
and discrepancies among the genomics, pathway or cellular functions across multiple
2
tumor types [114]. This kind of analysis gives insights on how one type of cancer
associates to another cancer types at genomic level, epigenomic level, transcriptomic,
pathway level and clinical level.
Following the literature review described above, this dissertation focuses on in-
tegrative analysis of radiogenomics, pathway genetic and epigenetic driver detection
applied in single cancer type and multiple cancer types, with the purpose of identi-
fying genomic and radiomic targets that significantly related with clinical outcomes,
target switches that drive pathway activity in one cancer and in pan-cancer appli-
cations. We mainly apply Bayesian methods for the integrative analysis where we
incorporate prior settings into the analyzing framework taking account of multi-scale
data sets, high dimensionality and similarity in the patterns of key factors across
multiple cancer types.
More specifically, in Chapter 2, motivated by “Bayesian methods for expression-based
integration of various types of genomics data” that was established by Jennings et
al., 2013 [49] which investigates clinical related genomic markers taking account
of molecular regulatory mechanisms. In this chapter, we develop a more in-depth
illustration of Radio-iBAG which refers to Radiomics-based Integrative Bayesian
Analysis of Multiplatform Genomic Data that further relates genomics with radiomics
and clinical outcomes. We apply our methodology framework to the case study of
glioblastoma multiforme (GBM), where we detect key genomic and radiomic markers
that are significantly associated with clinical outcomes.
We propose pathway integrative analysis in Chapter 3. This formulation allows
the investigation of how genetic and epigenetic drivers that significantly influence
specific pathway activity. We incorporate our analysis into colorectal cancer type
3
where it has four clear consensus molecular subtypes (CMS) [33]. We target to
dig into the pathway driver analysis searching for genomic upstream switches for
the key pathways that significantly di↵erentiate CMS groups. In Chapter 4, we
further extended the pathway analysis from single cancer type into multiple cancer
types where we detect pathway drivers for each cancer type in the group borrowing
strength of their potential similarities in the subset of the significant drivers with
Bayesian hierarchical modeling framework. We apply our methodology into di↵erent
cancer groups as in case study, such as Pan-kidney group, Pan-Gyno group [11],
Pan-GI group and Pan-Squamous group [18]. Finally, Chapter 5 contains conclu-
sion and future direction with an overview of the novelty, advantages and possible
improvement provided by the methodologies presented throughout the dissertation.
4
Chapter 2
Radio-iBAG: Radiomics-based
Integrative Bayesian Analysis of
Multiplatform Genomic Data
2.1 Introduction
In oncology, it is of critical importance to investigate both inter- and intra-tumor
heterogeneity through an in-depth understanding of the complex interplay between
genotypes and phenotypes, towards developing rational anti-cancer therapeutic
strategies [26]. The increased availability of complementary and matched molec-
ular and imaging data allows for a thorough examination of tumor heterogeneity
at multiple levels [85], [45], [34]. Investigations at the molecular level have been
tremendously improved by the development of many genomic profiling technolo-
gies, including microarrays, next-generation sequencing, methylation arrays, and
proteomic analyses. The Cancer Genome Atlas (TCGA) project, aiming to provide
more comprehensive information of human cancer genomes by creating an “atlas”
of high-throughput multiple genomic profiles across multiple cancers, was launched
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in 2005 as a publicly funded project [108]. The growing availability of such data
has motivated the development of integrative analytical models that incorporate
various genomic platforms to detect complex patterns of tumor heterogeneity that
have predictive and prognostic ability [112].
While genomic data provide information on the molecular characterization of a
disease, imaging modalities such as X-ray radiography, magnetic resonance imaging
(MRI), computed tomography, and positron emission tomography provide visual and
broad resources for the acquisition of high-quality images and provide complementary
quantitative information about the structural aspects of a disease. In the context of
cancer, these imaging modalities provide a quantitative basis for detailed assessment
of various features of the tumor that are associated with the development and pro-
gression of cancer. Radiomics is an emerging field with a goal of providing predictive
or prognostic information by revealing quantitative mechanistic associations between
radiologic images and clinical outcomes [23], [2], [27], [64]. Radiomics, in general,
involves the extraction and mining of various types of quantitative imaging features
that are processed from high-throughput images obtained via di↵erent imaging
modalities. These imaging features describe di↵erent morphological characteristics
of a tumor, e.g., tumor shape features such as round or spiculated, total volume
or surface area, intensity histogram features that describe the contrast intensity
level, and textural features such as energy and entropy that evaluate tumor spatial
heterogeneity. In particular, “texture analysis”, which applies di↵erent statistical
models and mathematical transforming methods to further evaluate a tumor’s
intra-lesional heterogeneity, has become an active ongoing area of research [20]. In
the context of glioblastoma multiforme (GBM), several studies have shown that
the textural features from perfusion parametric maps provide useful information for
predicting patients’ survival times [64] and the features extracted from a gray-level
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co-occurrence matrix (GLCM) [38], [20] are e↵ective in discriminating tumor volu-
metric phenotypes [21].
Radiomic and genomic features capture complementary characteristics of the
underlying tumor, with radiomics capturing visual phenotypic information in the
tumor and genomics capturing its underlying molecular biology. Thus, it is of
interest to assess the interrelationships of these two types of features, a task termed
radiogenomics, and then collectively assess how these inter-related features correlate
with clinically relevant endpoints (e.g., survival, progression). From an analytical
standpoint, radiogenomic analysis faces several key challenges. First, incorporating
complex biological interactive mechanisms, both within and between multiple ge-
nomic platforms at the genomic (DNA), transcriptomic (mRNA) and epigenomic
(methylation) levels, is understudied in the radiogenomic framework. Second, the
high-dimensional nature of both the quantitative features of images and genomic
markers necessitates proper dimension reduction techniques and feature selection
methods. Third, the analysis becomes more complicated when we wish to link clinical
outcomes with genomic and radiomic outcomes in addition to modeling associations
between the radiomic and genomic measurements to provide potentially biologically
and clinically translatable results.
Multiple studies have addressed these challenges to various degrees. Taking ad-
vantage of multi-platform genomic data resources, additive models have been
developed that treat the features from di↵erent platforms in the same models,
although not explicitly modeling their interrelationships [24], [59]. Wang et al.,
2013 [112] proposed an integrative Bayesian analysis framework to integrate multi-
platform genomic data using hierarchical models that capture the natural mechanistic
relationships among the various molecular resolution levels. Jennings et al., 2012 [48]
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generalized the method to integrate various types of genomic platforms with a
single clinical outcome. These methods e↵ectively capture the biological interaction
within di↵erent molecular processes, but do not consider high dimensionality in the
outcomes. Olivares et al., 2013 [87] extended the above model with multivariate
correlated imaging outcomes. This approach models image markers in separate
linear models after applying a de-correlating procedure, but does not consider
patient-specific clinical outcomes. Stingo et al., 2013 [102] developed an integrative
Bayesian modeling approach for imaging-genetics that incorporates the binary disease
status as a clinical response, and developed a hierarchical mixture model that can
select discriminatory imaging regions of interest and their relevant single-nucleotide
polymorphisms simultaneously. Similarly, Batmanghelich et al., 2013 [10] developed
a joint probabilistic model of imaging and genetic features associated with disease
measures, to provide insights into how imaging biomarkers can serve as intermediate
phenotypes when detecting genetic and diagnostic associations. However, these
approaches only consider individual platforms and thus do not consider the interrela-
tionships among the various molecular resolution levels in their analytical frameworks.
In this Chapter, we introduce Radio-iBAG: Radiomics-based integrative Bayesian
analysis of multiplatform genomic data, an integrative multi-scale Bayesian frame-
work to perform radiogenomic analyses. Our goal is three-fold: first, to detect
explicit associations among di↵erent genomic platforms at the di↵erent molecular
levels; second, to treat the radiomic-based biomarkers as an intermediate pheno-
type (i.e., endo-phenotype), evaluate the molecular underpinnings regulating these
biomarkers and finally, evaluate the eventual associations with relevant patient-level
clinical outcomes (e.g., survival times). To accomplish these tasks, we construct a
multi-level regression-based modeling strategy: a first stage “genomic model” detects
the complex biological mechanistic relationships among di↵erent genomic platforms,
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a second stage “radiogenomic model” subsequently discovers the underlying asso-
ciations between gene-platform combinations and radiomic biomarkers. To assess
clinical relevance, a third level model “radiogenomic clinical model” uncovers the
associations between clinical outcomes and genomically-driven radiomic markers.
To address the high dimensionality in both the genomic and radiomic datasets,
we utilize Bayesian shrinkage-based priors to achieve sparsity and regularization
in the high-dimensional covariate space at various hierarchical levels. Specifically,
we employ scale-mixture of normal representations, that allow adaptive shrinkage
and borrowing strength within and across the di↵erent hierarchical levels. Our
methodology is motivated by and applied to a GBM case study, wherein we discover
multiple radiomic feature groups significantly associated with patients’ survival times
along with their mechanism of action through multi-platform genomics.
In Section 2.2, we introduce our modeling scheme, major components, model-
ing methods and biomarker detection for each modeling stage. In Section 2.3, we
illustrate our proposed model on the GBM case study with detailed description of
the radiomic features and genomic profile datasets, modeling results and biological
interpretations. In Section 2.4, we draw some conclusions and discuss some future
extensions and advancements.
2.2 Method: Radio-iBAG Model
2.2.1 Modeling stages
As mentioned above, our core construction of the Radio-iBAG model framework con-
sists of a multi-stage Bayesian hierarchical model. In the genomic model, we model
the complex biological mechanistic relationship among genomic data from di↵erent
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platforms capturing information at various molecular resolution levels (e.g., gene
expression, copy number and methylation). Subsequently, we carry the information
garnered from the genomic model into the second stage, the radiogenomic model, to
parse out the imaging-genomic correlations, which are then included as predictors
in the third stage, the radiogenomic clinical model. This procedure delineates the
image features that directly a↵ect clinical outcomes, as well as those that appear
to be modulated by combinations of genomic factors. This construction allows us
to discover strong relationships between imaging and genomics data, among the
genomic platforms, and identify which appear to be associated with clinical outcome.
Figure 2.1 illustrates the general multi-stage modeling scheme. In the first stage,
multiplatform genomic data sets are expressed as data matrices: XmRNA, XCN ,
XmiRNA or XMethy, each with rows as samples and columns as gene-level summaries
of the respective platforms. In stage II, we consider radiomic features (RFs) that
are preprocessed and extracted from imaging data sets, forming a data frame I with
columns as di↵erent features and rows as samples. In the final stage, we incorporate
into the model the clinical outcome, denoted as Y , which is a vector with the number
of elements as the sample size. The construction of each modeling stage is explained
in detail in the ensuing sections.
A. Genomic Model
Our genomic model involves the integrative modeling of multiplatform genomic
data sets. Modern genomics data is comprised of multiple platforms that contain
measurements at various molecular resolution levels, from DNA to mRNA to proteins,
and including epigenetic levels including alterations like methylation and microRNA
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𝑮𝑪𝑵 𝑮𝒎𝒊𝑹𝑵𝑨 𝑮𝑴𝒆𝒕𝒉𝒚 𝑮𝑶𝒕𝒉𝒆𝒓𝒔……
miRNA Methy
𝑰𝒎𝒊𝑹𝑵𝑨 𝑰𝑶𝒕𝒉𝒆𝒓𝒔
𝑰 𝒈 𝑰 𝒈𝑰 𝒈
𝑰𝑴𝒆𝒕𝒉𝒚
𝑰 𝒈 𝑰 𝒈𝑰𝒈
𝑰𝑪𝑵 ……
Stage I : Genomic Model
Stage III : Radiogenomic Clinical Model
Stage II : Radiogenomic Model
Figure 2.1: Schematic representation of the multi-stage modeling process. In
stage I, for each gene, model the relationship between mRNA and di↵erent upstream ge-
nomic platforms and partition mRNA expression into multiple parts explained by di↵erent
genomic platforms, CN: copy number alteration, miRNA: microRNA, Methy: methylation,
Others: gene expression that is explained by other factors; In stage II, for each radiomic
marker, apply Bayesian hierarchical model and partition the radiomic marker into di↵erent
parts modulated by multiple mRNA factors that are explained by various gene-platform
combinations and regard the residual as a non-gene-driven part denoted as Ig¯; In stage
III, apply Bayesian hierarchical model to investigate the relationship between segmented
radiomic factors with clinical outcome.
(miRNA) that a↵ect mRNA expression. These platforms capture complementary
information at the di↵erent molecular resolution levels, and together provide a more
complete picture of the underlying biology than any one platform. In this thesis
Chapter, we consider three genomic platforms: mRNA, DNA copy number (CN) and
miRNA, but the general models we introduce can incorporate any other platforms
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capturing upstream genetic and epigenetic information, as well. Also, for a specific
gene, we only take the genomic platforms mapped with this gene into our model, we
do not consider modeling coexpression or coregulation of the neighboring genes or
potential transcriptional regulators. Suppose NG=number of patients with genomic
information, J=total number of genomic platforms, and PG=number of target genes.
For our particular case, using copy number alteration and miRNA as our upstream
platforms, the gene expression level can be modeled and expressed as
XmRNAg = f1(XmiRNAg) + f2(XCNg)| {z }
upstream platform driven
+ Og|{z}
explained by other factors
(2.1)
where each fj(·) is a smooth nonparametric function of the corresponding predictor
modeled by a penalized spline formulation that allows us to capture flexible non-linear
relationships. We assessed the nonlinearity of gene-level fits and show that GAM
provides better fit that GLM for most genes (see Appendix A.3). Other types of
splines or alternative nonparametric models could also be used. Our analysis in this
stage matches the first stage of the iBAG model [112], whereby the gene expression
of a given gene is modeled as explained by upstream factors, with the e↵ects of
upstream factors modeled nonparametrically as in [50] via a generalized additive
model (GAM) [40]. In principle, the model can include any number of upstream (to
mRNA) platform types, including methylation, copy number, loss of heterozygosity,
methylation, miRNA, and transcription factors, as long as matched data are available.
The terms in the model are described and interpreted as follows:
• XmRNAg is the expression of gene g with dimension NG ⇥ 1, g = 1, 2, ..., PG
• XmiRNAg is an aggregated miRNA expression value that integrates information
across miRNAs that have been documented to regulate the expression of gene
g. For a given gene, there exist multiple miRNAs that interact with this gene,
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and here we construct gene-level summaries of these miRNAs that condense
their activity into a lower dimension using principal components, as described
in detail in Section 2.2.3. The gene-level summaries XmiRNAg have dimension
NG ⇥ MmiRNAg , where MmiRNAg denotes the number of gene-level summary
vectors for the gth gene.
• XCNg are gene-level summaries of the CN alteration for the gth gene with di-
mension NG⇥MCNg . Similarly, as there are multiple CN alteration values from
di↵erent markers within the same gene, MCNg denotes the number of gene-level
summary vectors.
• Og represents the “other” part of gene expression that is not captured by the
modeled upstream factors, but instead attributed to other upstream factors not
in the model, and is of dimension NG ⇥ 1.
This model is fit separately for each gene, and e↵ectively partitions the infor-
mation contained in the mRNA measurements into an additive set of com-
ponents, with each component capturing the part of mRNA expression ex-
plained by a particular upstream platform. We call these parts di↵erent ge-
nomic platform components. For gene g, the components can be estimated
based on the following formula: GmiRg = fˆ1(XmiRNAg), GCNg = fˆ2(XCNg) and
GOg = XmRNAg   fˆ1(XmiRNAg)   fˆ2(XCNg). Repeating the same procedure
for all the genes, we combine the components grouped by platform, forming
di↵erent genomic platform combinations: GmiR = {GmiR1 , GmiR2 , ..., GmiRPG },
GCN = {GCN1 , GCN2 , ..., GCNPG } and GO = {GO1 , GO2 , ..., GOPG }. These combina-
tions represent the gene expression level attributed to miRNA, CN and other factors,
respectively, for all PG target genes of interest.
At times, not all samples with genomic data have radiomic data, as in our GBM
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example. In that case, we denote NGI (NGI ✓ NG) as the sample size of their inter-
section. We carry forward the corresponding subset of the estimated gene platform
combinations GmiR, GCN, GO, each with dimension NGI ⇥ PG, as predictors into
the second-stage radiogenomic model.
B. Radiogenomic Model
The goal of the second stage radiogenomic model is to find gene-platform com-
binations that appear to be associated with radiomic markers, and to partition the
radiomic markers into the parts modulated by di↵erent gene e↵ects carried from the
genomic model and those that are not modulated by the modeled genomic factors.
The model can be written as
I = Ig + Ig¯
= GmiRBmiR +GCNBCN +GOBO| {z }
Genomically driven
+ Ig¯|{z}
Non-genomically driven
(2.2)
The terms in the model can be expressed and interpreted as follows:
• I denotes a NGI⇥K matrix in which K is the number of general RFs (individual
radiomic features or Radiomic-meta-Features (RmFs) that we constructed from
high dimensional RFs that are highly correlated, described in detail in section
3.2).
• BmiR is of dimension PG ⇥ K, with columns as the vectors of the expression
e↵ects for corresponding radiomic markers through miRNA;
• BCN is of dimension PG ⇥ K, with columns as the vectors of the expression
e↵ects for corresponding radiomic markers through CN;
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• BO is of dimension PG⇥K, with columns as the vectors of the expression e↵ects
for the corresponding radiomic markers through “other” genomic mechanistic
factors;
• GmiR, GCN, GO are the estimated gene expression components described in
part A.
Associations are detected by examining the coe cients’ posterior probabilities based
on Markov chain Monte Carlo (MCMC) samples, and estimates given by posterior
means. To achieve the segmentation of the radiomic features, we can estimate each
component by IˆCN = GCNBˆCN , IˆmiR = GmiRBˆmiR, IˆO = GOBˆO. The final non-
gene-driven part can be estimated by Iˆg¯ = I GCNBˆCN GmiRBˆmiR GOBˆO. We
then further carry the above four components into the final stage, the radiogenomic
clinical model.
C. Radiogenomic Clinical Model
The third-stage model relates the various radiogenomic marker combinations from
the second stage model to a clinical outcome (e.g., survival time in our context). The
model can be expressed as
Y = ICN↵1 + ImiR↵2 + IO↵3 + Ig¯↵4 + ✏,
where Y is the clinical outcome with dimensionNGIC⇥1 andNGIC (NGIC ✓ NGI ✓ NG)
is the sample size of the intersection of the genetic, image and clinical data sets. ICN
is the CN modulated radiomic marker component matrix. Similarly, ImiR denotes
the microRNA modulated part; IO is the part of radiomic features explained by
a genomic factor but modulated by something other than CN or miRNA; and Ig¯
denotes the part of the radiomic feature not regulated by genes in the model. All
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four radiomic marker components have the dimension NGIC ⇥ K. ↵1, ↵2, ↵3, ↵4
denote the corresponding image marker combination e↵ects. ✏ is the error term for
modeling the clinical outcome. In our GBM application, where the clinical outcome
is survival time, we use an accelerated failure time (AFT) model, with Y as the
log-transformed survival time [113]. However, for the general analytical process, our
outcome Y can involve any clinical measurements with suitable regression model
determined by the type of outcome (e.g., logistic models for binary outcomes or Cox
proportional hazards models in the presence of censored outcomes.)
Our goal in this final stage is to identify radiomic markers associated with clin-
ical outcome, either modulated by genomic factors or not. We identify these factors
by estimation and Bayesian posterior inference of ↵ = {↵1,↵2,↵3,↵4}, and then
can characterize these e↵ects in more detail by tracing information back through
the earlier stage models. For example, if a particular radiomic feature is related
to clinical outcome through a genomic e↵ect, we can examine the corresponding
second stage model to identify which genes are driving such e↵ects, and then the
first stage model for those genes to find which upstream platforms most strongly
modulate the expression of those genes. In this way, the radio-iBAG model can not
only detect clinically relevant radiomic features, but provide a thorough summary of
the radiomic-genomic and multi-platform genomic interrelationships that appear to
modulate these factors.
2.2.2 Radio-iBAG Model Estimation
Our second- and third-stage models involve multiple genes and/or RFs, so it is
necessary to introduce sparsity into the regression models to regularize the fitting
and to obtain a relatively smaller and more interpretable set of radiogenomic factors
that appear to be related to the clinical outcome. This can be done using penalized
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likelihood or other regularization techniques, but here we use a Bayesian approach
and induce sparsity through the prior distributions on the regression parameters.
Some commonly used sparsity priors involve a discrete-mixture prior consisting
of a point mass at zero for noise and a continuous density distribution for signals,
for example a normal distribution and a point mass at zero [75]. Other types
of sparsity priors do not have a zero component, but instead are absolutely con-
tinuous distributions that accomplish sparsity via nonlinear shrinkage, which can
often be accomplished using a normal scale mixture prior distribution. Examples
include a normal-exponential (Bayesian lasso) [88], Horseshoe [19], generalized
double pareto [6], Dirichlet Laplace [13], and Normal Gamma [32]. Considering
incorporating the multi-scale property of the datasets by allowing common platform
share the same hyperparameters with proper biological interpretation, we seek for
prior settings that yield to more direct incorporation. Thus, we mainly consider
Bayesian Lasso and Normal Gamma prior settings. While the Bayesian lasso, which
is a Bayesian analog to the commonly-used lasso [107], is commonly used, it has
limited flexibility given it is determined by a single hyperparameter that regulates
both sparsity and the tails. We instead use the normal-gamma (NG) prior [32],
which contains a second hyperparameter, and thus can better handle sparsity as well
as flexibility to manage the tails and yield to more accurate coe cient estimates, as
described and illustrated via multiple simulation settings in [32]. We apply this prior
in both stage II radiogenomic and stage III radiogenomic clinical models. Further,
we allow the sparsity hyperparameters to be indexed by platform, which enables
borrowing of strength across genes in determining the desired sparsity and tail levels
on a platform specific basis.
To estimate the coe cient vector, for the kth RF, we assign the NG prior dis-
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tribution to  k = { kmiR, kCN , kO}, each part of the coe cient vector being
assigned with a particular set of the hyperparameters. In this way, we allow priors
settings that incoporate multi-scale datasets. More specifically, suppose our genomic
platform combination predictors can be expressed as X = {GmiR,GCN,GO}, then
the linear regression model and its hierarchical prior setting can be expressed as
Ik = X k + Ikg¯
Ik ⇠ Normal(X k,  2kINGI )
 k ⇠ Normal(0P˜ , D )
D = diag( 1,1, 1,2, ..., 1,P1 , 2,1, 2,2, ..., 2,P2 , ..., J,1, J,2, ..., J,PJ ),
where P˜ = P1 + P2 + ... + PJ is the total number of predictors (dimension of X),
J denotes the total number of platform types (j = 1, 2, 3, ..., J , here our J = 3),
and Pj denotes the total number of genomic features (each sub-indexed as g) for the
jth genomic platform type. Our estimation of the scale parameters and the main
coe cients ( k) is processed by applying the NG prior  j,g ⇠ Gamma( j, 1/(2 2j ))
for the jth platform. Also, the hyper-prior  j ⇠ exp(c) and   2j ⇠ Gamma(a˜, b˜/(2 j))
are assigned to induce greater flexibility and completeness in shrinkage estimation.
To complete our prior specification, we assume a conjugate InverseGamma(a, b)
prior on  2k. Here, we let each genomic platform combination (platform type) share
the same set of hyperparameters ( j,  2j ), thus maintaining the grouped struc-
ture at the shrinkage level. For implementation, we utilize Markov Chain Monte
Carlo (MCMC) based Bayesian sampling techniques such as Gibbs sampling and
Metropolis-Hastings. The posterior means calculated from MCMC samples are used
to obtain the parameter estimations, and the corresponding posterior probabilities
are used to conduct signal detection. The details for the posterior distribution and
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MCMC sampling are shown in Appendix A.1.
For the radiogenomic clinical model, we utilize similar NG prior distributions,
the only di↵erence being that our group structure is determined by the RF com-
binations. We assign the same hyperparameters for the partitioned RFs that
belong to the same combination/group. Suppose our predictor set estimated from
stage II can be expressed as I = {ICN ,ImiR,IO,Ig¯}, and the e↵ect parameter
↵ = {↵1,↵2,↵3,↵4}, then the model and prior construction can be expressed as
Y = I↵+ ✏
Y ⇠ Normal(I↵,  2INGIC)
↵ ⇠ Normal(0, D )
D = diag( 1,1, 1,2, ..., 1,K , 2,1, 2,2, ..., 2,K , ..., J,1, J,2, ..., J,K),
where J denotes the total number of di↵erent RF combination types (j = 1, 2, 3, ..., J ,
our J = 4), k denotes the RF index (k = 1, 2, 3, ..., K). Further, we as-
sign our prior and hyper-prior distributions as  j,k ⇠ Gamma( j, 1/(2 2j )),
 2 ⇠ InverseGamma(u1, u2),  j ⇠ exp(d), and 1/(2 2j ) ⇠ Gamma(e˜, f˜/(2 j)).
Note that for censored sample i, we sample Yi from complete conditional distribution
which is normal distribution with left truncation at ti that represents the follow-up
time. Finally, RF combination selection is based on the posterior probability of the
MCMC samples. Details about the posterior distribution and sampling methods are
provided in Appendix A.1.
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2.2.3 Radiomic and Genomic Marker Selection
For marker/feature selection we propose a thresholding procedure for the various
regression models. Specifically for the radiogenomic clinical model, we choose a
thresholding criteria considering both the e↵ective size and clinical interpretability.
For example, in the GBM case study, we apply the AFT model with the log-
transformed survival time as the clinical outcome. In our analysis, considering that
the survival times are measured in months, which is comparatively small, we choose
to apply log2-based transformation, which leads to better interpretability and a sim-
pler calculation. Based on this setting, the region for detecting the coe cients of the
image markers becomes ↵jk 2 ( 1,  ⇤ )[ ( ⇤+,1), where we denote  ⇤  as log2(1   2)
and  ⇤+ as log2(1 +  2), particularly, ↵jk is the coe cient of the k
th radiomic marker
modulated by the jth genomic platform (j = 1, 2, ..., J , k = 1, 2, ..., K). Moreover,  2
is determined to achieve the proper e↵ect size and is interpreted as the percentage
change in survival time, e.g., for the GBM data analysis, we choose  2 = 0.05,
which corresponds to 5% change in survival time. More specifically, we denote
P+(Ijk) =
Pt=T
t=S+1 I(↵
(t)
jk >  
⇤
+)/(T  S) and P (Ijk) =
Pt=T
t=S+1 I(↵
(t)
jk <  
⇤
 )/(T  S)
where t denotes the tth MCMC iteration, S denotes the burn-in sample size and
T represents the total number of MCMC iterations. We flag Ijk to be positively
significant if P+(Ijk) > 0.5 or negatively significant if P (Ijk) > 0.5 [9].
Analogously, for the radiogenomic model, considering  -fold or larger variation
in the response for a unit change in a particular predictor is defined as a stan-
dard in the significance detection, which corresponds to  jg 2 ( 1,  ) [ ( ,1)
and  jg is the coe cient of the jth platform of the gth gene in the analysis.
Once a proper threshold  1 is determined, the posterior probability is defined as
P (xjg) =
Pt=T
t=S+1 I(| (t)jg | >  1)/(T   S), where S is the burn-in sample size and T is
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the total number of MCMC iterations. Feature xjg in the gene-platform combinations
is highlighted to be ‘significant’ if P (xjg) > 0.5.
Radio-iBAG modeling algorithm provides a concise summary of Radio-iBAG model
implementation and genomic/radiomic marker selection.
2.3 Radiogenomic Mapping of Glioblastoma Mul-
tiforme
Glioblastoma Multiforme (GBM) is an aggressive and malignant form of primary
brain cancer. It is the highest grade glial tumor, with a median survival time of
14.6 months following standard treatment options and typically 3 months without
treatment [103]. Although di↵erent treatment approaches that include radiation,
surgery and chemotherapy have been developed and applied in clinical practice, the
overall mortality rate still remains high, mainly due to the tumor’s resistance to
treatment [14] and the complexity of its primary biological mechanism.
Currently, at the molecular level, TCGA provides data sets with multiple ge-
nomic platforms, including methylation, CN alteration, and gene expression. Studies
based on TCGA platform have identified distinct molecular subclasses of GBM,
resembling stages in neurogenesis that are relevant to prognosis [110]. Also, with
the availability of standardized medical image annotations from The Cancer Imag-
ing Archive (TCIA), multiple studies currently focus on the detection of radiomic
imaging variables associated with clinical outcomes [21], [55]. Relevant studies have
shown that quantitative imaging features extracted from di↵erent modalities provide
strong prognostic information [85], [64].
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Radio-iBAG modeling algorithm
Stage I: Genomic Model
for each gene g do
XmRNAg = f1(XmiRNAg) + f2(XCNg) +Og
Estimate GmiRg = fˆ1(XmiRNAg), GCNg = fˆ1(XCNg)
and GOg = XmRNAg   fˆ1(XmiRNAg)  fˆ2(XCNg)
end for
aggregate: GmiR = {GmiR1 , GmiR2 , ..., GmiRPG}; similarly for GCN and GO
Stage II: Radiogenomic Model
for each RF k do
Ik = GmiR kmiR +GCN kCN +GO kO + Ikg¯ = X k + Ikg¯
MCMC sampling of  jg (j: platform; g: gene index) for T iterations.
Calculate posterior probability with burn-in sample size S.
if P (xjg) =
Pt=T
t=S+1 I(| (t)jg | >  1)/(T   S) > 0.5 then
xjg (g: gene index; j: platform index) is flagged as important
end if
Estimate  jg by posterior mean:  ˆjg =
1
T S
Pt=T
t=S+1  
(t)
jg
segment  ˆk = { ˆ11,  ˆ12, ...,  ˆJPJ}T = { ˆkmiR,  ˆkCN ,  ˆkO}T
Thus Iˆkg = GmiR ˆkmiR +GCN ˆkCN +GO ˆkO = IˆkmiR + IˆkCN + IˆkO
and non-gene-driven part Iˆkg¯ = Ik   Iˆkg
end for
aggregate: ImiR = {Iˆ1miR, Iˆ2miR, ..., IˆKmiR}; ICN = {Iˆ1CN , Iˆ2CN , ..., IˆKCN};
IO = {Iˆ1O, Iˆ2O, ..., IˆKO } and Ig¯ = {Iˆ1g¯, Iˆ2g¯, ..., IˆKg¯}
Stage III: Radiogenomic Clinical Model
predictor matrix I = {ICN ,ImiR,IO,Ig¯}
coe cient vector ↵ = {↵1,↵2,↵3,↵4}
modeling: Y = I↵+ ✏
MCMC sampling of ↵jk (j: RF combination group, k: RF index within each group)
for T iterations.
Calculate posterior probability with burn-in sample size S.
if P (Ijk) =
Pt=T
t=S+1 I(|↵(t)jk | >  2)/(T   S) > 0.5 then
Ijk (j: RF combination group index; k: RF index) is flagged as significant.
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The availability of such large-scale data resources (TCIA and TCGA) makes it
feasible to perform radiogenomic mapping in GBM to explore the complex associa-
tions between molecular features and imaging features for this particular cancer type.
In this section, we apply our integrative multi-stage Bayesian hierarchical model with
the data from patients with GBM and matched with TCGA and TCIA platforms, to
discover radiogenomic associations characterizing these data and identify RmFs and
genomic markers associated with GBM prognosis. More details of the genomic and
imaging data sets are provided hereafter.
2.3.1 Data Description
2.3.1.1 Radiomic and clinical data description
Among 304 GBM patients with available genomic records, 78 matched patients
(NGI=78) also have MRI T1-weighted post contrast images and T2-weighted fluid
attenuated inversion recovery (T2-weighted FLAIR) images available from TCIA
for texture analysis. Image preprocessing procedures, including steps such as
non-uniformity normalization (N3) correction, registration, segmentation, isotropic
voxel-reslicing and image filtering, were performed prior to texture feature extraction.
For this analysis, we derived textural features from the axial 2D slice that has the
largest tumor area [122]. Our textural features were obtained from a two-step
process: 1) Image filtering, 2) Haralick features1derivation [38] [36] and summary
measures calculation. These image pre-processing steps as well as the texture feature
calculations are described in detail in the Appendix Section A.2.
For the radiomic data set, we had 972 RFs that could be categorized into 20
groups based on how they were calculated. The group names and corresponding
1Features generated using various metrices of the co-occurence matrices are called “Haralick
features” after the publication of [38].
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descriptions are provided in the Appendix Table A.3. They cover the features of both
T2-weighted FLAIR and T1-weighted post-contrast MRI modalities with di↵erent
type of features: texture features, histogram features and regional features and with
two types of ratio based normalization methods.
For clinical outcomes, we utilized overall survival times (in months) as the re-
sponse in our integrative analysis. For the clinical model, we used data from
NGIC = NGI = 78 GBM patients with matching multi-platform genomic, radiomic,
and clinical data, and with 9 patients having censored clinical outcomes. We applied
the AFT model using the log2 transformed survival time log2(Ti) as the response,
where Ti is the survival time in months after diagnosis for patient i, and imputed the
survival time for censored samples simultaneously.
2.3.1.2 Genomic data description
Our gene expression data set is level 3 (summarized per gene), and was downloaded
and processed by TCGA Assembler [123] with open-source software and related in-
structions available in public. The CN data set is level 2 (probe-level) data obtained
from TCGA Portal from the HG CGH 244A platform with normalized records of
CN alteration for each probe. The miRNA data set was also acquired from TCGA
Portal with 534 miRNA records and 575 samples in total.
In our analysis, we focus on 49 genes that are members of signaling pathways
that have previously been detected associated with GBM (RTK/PI3K, P53, and
RB pathways [84]) and 304 patients (NG = 304) with records available for mRNA,
CN and miRNA. The sample sizes and the specific types of the raw datasets for
all genomic platform, radiomic data and clinical data are illustrated via diagram in
Appendix Figure A.3 with description in Section A.2.3. The genomic datasets used
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in the first stage are all continuous and the descriptions of the raw data structure
(for 304 samples) of di↵erent genomic platforms are given in below:
• mRNA (304⇥ 49) contains gene expression levels for each gene and each patient.
• Copy number (304 ⇥ 491) contains the CN alteration data (columns) for each
sample (rows). There exist multiple copy number markers per gene, and the
columns of the data set are sorted by gene. Also, one gene, HRAS, does not have
CN alteration information, thus, any variance of gene expression contributed by
CN changes will be captured by the factor “others” in this analysis; in other
words, for gene HRAS, the corresponding column in matrix GCN is set as zero.
• miRNA (304 ⇥ 522) contains miRNA values for each gene (column) and pa-
tient (row) based on the miRNA-mRNA interaction membership matrix, with
records coming from targetHub [69], which collected miRNA-mRNA interac-
tion records based on 5 external databases, and multiMiR [93] is based on 14
external databases, including validation databases, prediction databases and
drug-associated databases. There exist multiple miRNA records corresponding
to one gene, and the columns of the miRNA data set are ordered by gene.
We wish to obtain gene-level summaries for each platform based on these raw data
sets. Considering that a given gene can contain multiple values from di↵erent
markers for both miRNA and CN alteration records, and including all these records
into the genomic model is computationally expensive and ine cient, the gene-level
summaries that can be carried into the modeling stage need to be generated. There
are di↵erent ways to obtain gene-level summaries, e.g., taking the average, selecting
the top most correlated records, or extracting the top principal components via
PCA. For the analysis of GBM data, CN alteration and miRNA, in each case, we
perform PCA on the genomic platform data set mapped to a gene and keep the
top principal components with cumulative variance that explain up to 90% of the
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total variance. In this way, we regard the remaining records as capturing most of
the information of the genomic platform data. Specifically, for gene g, the gene-level
summaries for each platform can be expressed as XmiRNAg and XCNg , which have
been denoted in Methods. Our genomic model is conducted based on these three
data sets, XmRNAg ,XmiRNAg and XCNg .
As described in Section 2.2.1, our genomic model uses the GAM to fit the model and
estimate the partitioned mRNA that is modulated by di↵erent genomic platforms. To
implement the GAM algorithm, we utilized Wood’s R package “mgcv” and exploited
its option for the automatic smoothness selection for the penalty parameter based
on generalized cross-validation [117]. Subsequently, for each gene, we calculated the
proportion of the mRNA variance explained by each platform. We assume that if
a genomic platform does not explain much variation in mRNA expression, it will
not have a significant impact on image features. Thus, for GmiR, GCN and GO, we
filtered out the genomic platform features that explain less than 10% of the total
variance of gene expression, leaving the remaining features to be carried forth into
the radiogenomic model.
2.3.2 Estimation of Radiomic-meta-Features
One of the critical challenges in fitting the radiogenomic model is the high dimension-
ality and redundancy of the set of radiomic features (RFs). In our GBM case study,
the preprocessed RF data set has 972 features, and contains many features within
the same type of radiomic class but with di↵erent settings, e.g. filtering scales. Thus,
there are extensive correlation among many RFs with high magnitudes up to 0.99, as
can be seen in the correlation heatmap shown in Appendix Figure A.1. Facing these
challenges, we utilize a new radiomic strategy of empirically constructing radiomic
meta features (RmFs) comprised by a linear combination a sparse subset of highly
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correlated RFs. Each RmF defines a factor capturing one aspect of the fundamental
structure in the radiomic features, and together the relatively small number of
RmFs retain a vast majority of information contained in the set of 972 RFs. To our
knowledge, this strategy has not been applied in the radiomics literature to date, and
may be useful in other contexts. We construct the RmFs by applying sparse principal
component analysis (sPCA) [125] which incorporates a regularization technique such
as the lasso or elastic net to induce sparsity in the principal component loadings.
This has the advantage of interpretability over general principal components that
do not in general yield sparse loadings, in the case of our GBM application yielding
RmFs that are reasonably intuitive and interpretable (see Section 2.3).
This algorithm o↵ers a parsimonious way to obtain more comprehensive repre-
sentation of radiomic features, which contain the maximum information of the
original radiomic data. While not strictly orthogonal like PCs, the SPCs are approx-
imately orthogonal so it is reasonable to model these RmFs as independent imaging
features in the second stage radiogenomic model. The sparse loadings for the RmFs
for our GBM application are shown in Figure 2.2, and by contrast, the non-sparse
loadings for ordinary PCA are shown in the Appendix A.2.2 Figure A.2.
Let M be an NGI ⇥ P matrix (typically with P >> NGI) with the rows being
the subjects and the columns the P (=972) RFs. The sparse PCA is applied as
follows:
• Apply ordinary PCA to M and record the number of top principal components
with the cumulative variance explaining up to 100(1 ↵)% (eg. 90%) of the total
variance. Each PC is regarded as a linear combination of the original features
with its loadings can be estimated by regressing the PC on these features.
Sparsity in loadings results from adding regularization terms in the regressions.
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• The general sPCA algorithm and its numerical computation procedure are de-
scribed by [125]. In most cases, the number of features is typically much bigger
than the sample size; hence, the simplified version of the general sPCA described
in the this Chapter should be applied here. The mathematical formulation of
sPCA is illustrated in the Appendix A.2.2. To implement the algorithm, we
utilized the R package “elasticnet” [124], with K (the number of principal com-
ponents based on the ordinary PCA) principal components and vectors of  j
(L1 norm regularization parameter for each loading vector). The parameter  j
can be chosen by cross validation, or various values can be tried to find one that
results in the desired level of sparsity.
Suppose V is our final matrix of loadings with dimensionality P ⇥K, the projected
imaging features matrix (PC score matrix) is then I(NGI⇥K) = M(NGI⇥P )V(P⇥K).
We define the vectors of this matrix as RmFs, which contain the majority of the
information of the original radiomic data. These features are further regarded as
predictors in the analysis of the radiogenomic clinical model.
2.3.3 Results Using the Radio-iBAG Model
2.3.3.1 Radiomic-meta-Feature Estimation
We conducted sPCA with the regularization parameter   = 2.5 for each principal
component, leading to 22 top principal scores that explain 80.7% of the total vari-
ance. Through the exploration of the results utilizing di↵erent   values, we finally
chose   = 2.5 given its balance in the sparsity of the loadings which leads to good
interpretation and the cumulative variance that could be attained. We call these
22 principal scores Radiomic-meta-features (RmFs) as discussed in section 3.2. To
summarize the RmFs, plots a heatmap of the squared loading proportions within the
20 broad categories of RFs to show which feature types dominate each RmF.
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Figure 2.2: Squared loading proportion for each RF group. For each of the 22
radiomic-meta-features (RmFs), the sum of the squared loadings of each group is calculated,
divided by the total sum of the squared loadings, which equals exactly 1. The heatmap
shows this values in grey level, interpreted the RF group importance for each RmF. The
grey level ranging from white to black matches the proportional values ranging from 0 to 1.
This figure reveals that many of the RMFs appear to be interpretable in the sense of
summarizing certain aspects of the images, including morphological imaging features
that can be directly visualized, eg. unformity, tumor area, mean intensity, etc. To
further illustrate their interpretability, we pick out three example RmFs and in
Figure 2.3 plot T1-Post Contrast images for the four tumors with highest and lowest
values of the corresponding RmF scores, rescaled to [0,1]. RmF 21 has the largest
loading values for feature categories indicating tumor area (T1 Region, F Region).
The first column of Figure 2.3 shows that samples with higher values of RmF 21
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tend to have larger tumor area. RmF 14 has non-zero loadings inversely proportional
to pixel intensity variance measures, and thus can be construed as representative of
local pixel heterogeneity. From the second column, it is evident that larger RmF
14 (smaller variance) leads to lower local pixel heterogeneity. The third column of
Figure 2.3 shows the sorted RmF 17, whose loadings are dominated by the imaging
intensity histogram feature “uniformity”, which represents how non-uniform of the
overall gray-level pixel intensities. The gray level of the magnified tumor region
shows that when RmF value gets larger, the tumor surface gets more non-uniform.
These RmFs quantitatively capture these fundamental features of the images.
We use these RmF as quantifications of the radiomic data in our modeling, with the
radiomic model fit to Rmf matrix I , which is of dimension 78 ⇥ 22, with RmFs as
columns and subjects as rows.
2.3.3.2 Radio-iBAG Modeling Results
Our model shows proper convergence and it is not sensitive to the choice of the hy-
perparameters based on the model checking results respectively described and shown
in Appendix A.4.2. After model fitting, the information about the prognostic radio-
genomic features can be explored in the following sequence: RmFs that significantly
influence the survival time, either positively or negatively, are selected using our cri-
teria outlined in Section 2.2.3. For each selected RmF, the important RF groups
comprising this RmF can be identified by evaluating the sPCA loading information
as shown in Figure 2.2. To obtain significant genes and genomic platforms for the
selected RmFs, we then trace back to the radiogenomic model and the genomics
model, to identify which genes, if any, are associated with that RmF, and then which
upstream platforms appear to be modulating the genomic e↵ect. The specific results
for each stage are described here.
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Figure 2.3: T1-Post Contrast images are shown based on the sorted results of 3 represen-
titive RmFs: RmF 21 mainly accounts for tumor area; RmF 14 mainly represents tumor
pixel heterogeneity; RmF 17 represents tumor uniformity. The RmF values are all scaled
from 0 to 1.
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2.3.3.2.1 Radiomic Results
We use posterior probabilities to detect significant radiomic signals as well as ge-
nomic platform factors in both stage II and stage III based on the median probability
criteria described in Section 2.2.3. Figure 2.4 shows the posterior probabilities used
to select the positively and negatively significant clinical RmF combinations. The
results show that more RmF are positively significant for the prognostic outcome,
with 1 unit change leading to at least 5% increase in survival time ( 2 = 0.05). Also
negatively selected significant RmF combinations have the interpretation as 1 unit
change leading to at least 5% decrease in survival time. Based on Figure 2.4, we see
that RmF 7 and RmF 8 have a positively significant influence on the survival time,
with the parts that are modulated by genes through their copy number e↵ects (GCN).
RmF 1 and RmF 3 are negatively associated with survival with the parts that are
modulated by genes through their copy number e↵ects (GCN). RmF 1, RmF 4, RmF
8, RmF 18 and RmF 21 are positively related with survival via genemic e↵ects not
modulated by CN and miRNA. RmF 10 and RmF 19 are negatively associated with
survival through genomic e↵ects not modulated by miRNA nor CN. RmF 13, RmF
14 and RmF 21 are positively associated with survival apart from genetic modulated
factors.
To interpret the flagged RmFs, we turn to Figure 2.2, which illustrates how
much variance each RF group contributes to the corresponding RmF combinations.
RmF 8 is found to be positively associated with survival through CN e↵ects, and
Figure 2.2 shows that RmF 8 is dominated by the the RF groups “T1 LoG Tex R1”
and “T1 LoG Tex Fine”. RF names and their brief interpretations are shown in the
table of Section A.2.2 of Appendix. In general, we see that texture features derived
from T1-weighted post contrast images processed with R1 normalizing approach tend
to be more significant, and based on the actual loading values, we found Haralick
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features to be important, including sum average and inverse di↵erence moment. As
another example, RmF 19 modulated by gene expression not explained by miRNA or
CN changes (GO) is detected to be negatively associated with survival, and for this
RmF the dominant RF group is the Haralick features extracted from T2-weighted
FLAIR images, especially with exact features named cluster shade, cluster promi-
nence, energy and contrast. Additionally, RmF 21, which is found to be positively
associated with survival both through genomic factors explained by“other” and
the non-gene driven part. Further checking found that RmF 21 is associated with
T1-weighted post contrast and T2- weighted FLAIR tumor areas. This indicates
tumor area, as one of the major regional features, associated with the survival time
and seemingly moderated by gene expression of signaling pathway genes, in part
regulated by some genomic transcriptional factors other than CN or miRNA.
Radiomic Biological Significance
In general, more radiomic features extracted from T1-weighted post contrast MRI
images are selected to be clinically significant and most of them appear to be asso-
ciated with genomic e↵ects in signaling pathways. This is not unexpected given the
fact that recent studies in literature showed that genomics are expected to be most
related to T1-weighted post contrast images rather than T2-weighted FLAIR prepro-
cessed ones. More specifically, RmF 14, which mostly captures the contrast margin
of the enhancing MRI image, the magnitude and the loading information, indicate
that higher texture feature sum of average or lower texture feature sum of variance
derived from the contrast of the edges leads to longer survival times. The detection
of RmF 10 shows that histogram features, derived from T2-weighted FLAIR image
pixel intensity and representing the global summary of the enhancement, are selected
to be primarily a↵ecting patients’ survival. It has been shown that the overall in-
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(a) positively significant RmF combinations (b) negatively significant RmF combinations
Figure 2.4: Results of stage III (radiogenomic clinical model): Detecting postively and
negatively significant RmF combinations. Each RmF is segmented into 4 parts, of which
3 parts are modulated by di↵erent genomic platform combinations denoted as ICN ,ImiR,
and IO. The 4th part is modulated by unknown/unmeasured factors represented as Ig¯
(“ng” in the legend). The barplot shows the posterior probabilities that the coe cient for
each part ↵jk >  ⇤+, where ↵jk denotes the kth RmF modulated by the jth genomic platform.
For each RmF, the probabilities of these 4 components, CN, miRNA, others, and ng, are
respectively shown in red, green, purple and blue. Each probability in Figure 2.4(a) shows
that 1 unit increment in the RmF component leads to at least 5% increase in survival time.
Each probability in Figure 2.4(b) shows that 1 unit increment in the RmF component leads
to at least 5% decrease in survival time. We consider the markers to be significant if this
posterior probability is larger than 0.5.
tensity is correlated with blood flow vasoconstriction. Moreover, we see associations
with several key genes PDGFRA and TP53, with genomic transcriptional factors that
a↵ect the uniformity of the overall pixel intensity. In addition, RmF 21, with both
genomic transcriptional factor driven part and non-gene driven part, are also selected
to be significant in influencing patients’ survival time. Since the region feature, more
specifically, tumor area, that captures most of the variation of RmF 21, our conclu-
sion indicates that tumor area calculated from both T1-weighted post contrast and
T2-weighted FLAIR images, are clinically important, larger area results in shorter
survival times.
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Figure 2.5: Significant genomic CN combinations
2.3.3.2.2 Genomic Results
For the selected RmFs, we trace back to stage II and obtain the regulating genes
that significantly a↵ect the RmFs through specific genomic platforms (CN, miRNA
or others), as shown in Figure 2.5, Figure 2.6 and Figure 2.7. To flag genes as
associated wtih the RmFs, we compute the posterior probabilities of the magnitude
exceeding a pre-specified threshold. For our analysis, we present the results with
the setting  1 = 0.075 in this section since it gave us the best balance between the
signal and sparsity. For the flagged genes, we traced back through the stage I model
to acquire the percentage values (marked in blue) that represent the proportion of
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Figure 2.6: Significant genomic mRNA “Other” combinations
the mRNA variance that is explained by the corresponding genomic platform. For
example, RmF 8 modulated by the CN combination is selected to be important,
referring to the top left graph in Figure 2.5, genes GRB2, PIK3CB, SPRY2 and
TP53 are selected as important, a↵ecting RmF 8 through CN alteration. For gene
SPRY2, 20.3% of its mRNA is explained by CN alteration. Also, genes PDGFRA
and TP53 are selected as significantly influencing RmF 10 via other transcriptional
factors. For TP53 in particular, the genomic factors (other than CN and miRNA)
explains 86.2% of its mRNA variance.
For the results of stage I, after performing genomic modeling and filtering out
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Figure 2.7: Significant genomic mRNA “Other” combinations
the genomic platforms that did not explain much of the variance of gene expression
(discussed earlier), there are 92 markers in the remaining gene-platform combinations
(miRNA: 12; CN: 31; Others: 49) being carried into stage II, the radiogenomics
model, as predictors. Figure 2.8 presents the overall genomic and radiomics results:
RmF 7 and RmF 8, modulated by CN, are selected to be positively associated with
survival time. Furthermore, 4 genes (GRB2, PIK3CB, SPRY2 and TP53), with their
part of gene expression (mRNA) explained by CN alteration, are detected as being
significantly associated with these RmFs. For the transcription modulated part, RmF
10 and RmF 19 are detected as being negatively important and associated with gene
ERBB2, TP53 and PDGFRA; while RmF 21 is positively significant and associated
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with genes CDKN2A, ERBB2, MDM2, PDGFRA, PIK3C2G and PIK3CG. For the
non-gene-driven factors, RmF 13, RmF 14 and RmF 21 are positively significant.
Figure 2.8: Results: Significant RmFs, genes and genomic platforms. Four cate-
gories of RmF combinations are listed in the first column, where “non gene” denotes “g¯,”
which is the non-gene-driven part of the RmF. For each category, several significant RmFs
detected from the clinical model are listed in the second column, with unbolded indicat-
ing positive ones; bolded indicating negative ones. Posterior probability of the important
radiomic markers is shown in column 3. For each selected RmF, several RF groups are
selected based on RmF description heatmap (Figure 2.2). For each significant RmF combi-
nation, significant genes are listed with the percentage of how much the variance of mRNA
is explained by the specific genomic platform.
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Genomic Biological Significance
Result table shows that gene EGFR is selected to be significant for multiple flagged
RmFs. It agrees with the literature that the aberrations and gene expression of
EGFR, with its full name as “epidermal growth factor receptor”, have been associated
with the classical subtype of GBM among 4 major subtypes (proneural, classical,
mesenchymal and neural), defined based on transcription data analysis [110]. This
particular subtype accounts for ⇠ 25%-30% of GBM cases. The amplification of the
EGFR gene is the most common genomic change that leads to overexpression of the
receptor variant III (EGFRvIII), and 20% or less EGFRvIII in GBM is significantly
related to longer overall patient survival [76]. Moreover, PDGFRA is another gene
which has been flagged as important for multiple RmFs. It was found that for the
proneural subtype, platelet-derived growth factor (PDGF) receptors (PDGFRAs)
have been found to represent gene [110]. Also, PDGFR has been positively correlated
with patient survival time and its critical role in oncology has been well described
in the context of gliomas [80]. Gene TP53 is selected to significantly influence RmF
8 via its mRNA explained by CN, and specifically, TP53 has been found to be the
main hub gene that acts as tumor suppressor through comparative analyses of CN
and mRNA expression in GBM tumor and xenografts [41]. The study illustrated
that loss of TP53 function in GBM leads to transcriptional upregulation in gene
expression network.
MDM2 is a commonly known oncogene that inhibits the tumor suppressor TP53;
its overexpression and amplification have been studied through the analysis of
CN alterations and gene expression profiles in previous studies [118]. The gene
CDKN2A, with other transcription factors accounting for its expression, has been
found to be significantly associated with tumor area for both T1-weighted post
contrast and T2-weighted FLAIR. CDKN2A belongs to the RB1 pathway, serves as
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a cyclin-dependent kinase inhibitor, and has been detected to be important [101].
It has been reported that loss of RB1 expression occurs in up to 25% of glioblas-
tomas. Changes in RB1 expression have been associated with alterations in tumor
cell proliferation and survival [56], [77]. Also, the assessment of RB1 promoter
hypermethylation showed a clear correlation between the loss of RB1 expression and
promoter hypermethylation [78]. Analysis of GBM on the molecular level (TCGA
data), using fluorescence in situ hybridization and immunohistochemistry, showed
that alterations in RB1 occur more commonly in the proneural subtype of GBM.
2.4 Discussion and Conclusion
This Chapter presents the radio-iBAG model, a general framework for multi-scale
integrative Bayesian analysis of radiogenomics data. Our hierarchical models in-
corporate biological mechanistic relationships among multiple genomic platforms,
radiomic feature analysis and radiogenomic analysis with relevant clinical outcomes.
There are three key features of this modeling strategy: (1) Multiple genomic platform
profiles are incorporated in the radiogenomics framework; (2) For model fitting, high
dimensionality with a pre-defined group structure in the covariates can be addressed
through Bayesian shrinkage priors. In particular, we choose the normal gamma
prior due to its flexibility in both shrinkage and parameter estimation; and finally
(3) Investigating the relationship between clinical outcomes and radiomic features
containing genomic information allows us to identify clinically significant genes,
radiomic features and more importantly, the hidden associations between these
two data modalities. We note that although our modeling strategy is motivated
by an imaging genomics study in GBM, our methodology is general and can be
applied to any other disease domain which generates quantitative imaging data
with matched genomic data. This includes neurological diseases where the imag-
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ing features could be computed from structural or functional neuroimaging assays [7].
We applied our methodology to the analysis of radiomic and genomic data sets
of GBM. Our model analyzed the relationship between the survival times of patients
and the RmFs modulated by various gene-platform combinations. Our analysis iden-
tified several RmFs that significantly impact survival times as well as identified the
key radiomic features driving these factors. These results revealed that some of the
most prognostically important radiomic features include tumor area, intensity his-
togram uniformity, and Haralick features derived from the GLCM, including energy
contrast, inverse di↵erence moment, and entropy for both T1-weighted post-contrast
and T2-weighted flair images. Based on the results of modeling the relationship
between RmFs and multi-platform genomic measurements, for each detected RmF,
we subsequently identified which gene-platform combinations modulated that RmF.
This allows us to detect prognostic RmFs modulated by upstream molecular plat-
forms such as copy number, microRNA or other factors. Furthermore, we were able
to identify which genes and platforms were driving these associations.
In summary, the advantages of applying integrative analysis of multiplatform
genomic profiles in this framework are illustrated through the hierarchical back-
tracking, which allows us to discover strong associations and interrelationships
among the clinical, image, and genomic factors that may help elucidate the underly-
ing biology. Most of the significant genes identified in our analysis have been shown
to be biologically and clinically relevant to GBM molecular subclassifications, cancer
development, or therapeutic strategies.
The Radio-iBAG model that we proposed has several limitations. First, from
clinical perspective, the model is more of an exploratory analyses that mainly inves-
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tigate biological regulatory mechanisms, thus, further work would have to be done
to establish its translational relevance. Also, the multi-level model that we construct
in this chapter is complex and takes careful thought to interpret. Another limitation
lies in that the model does not include clinical features especially the ones such as
age and Karnofsky score, that have been shown to have significant impact on survival
times of patients with GBM [86]. In addition, from the aspect of result validation, we
currently apply our method into GBM as case study merely based on the data sets
that come from one resource (TCGA), the results could be further validated from
other data resources, which will quantitatively lead to more consolidated detection
of genomic and radiomic markers.
Several possible future extensions and generalizations could be explored based
on our Radio-iBAG framework. For example, in our methodology, we applied a
multi-stage modeling strategy in doing integrative analysis. A possible advancement
may be using a joint model to capture all the relationships among di↵erent platforms
simultaneously and maintain the detective power with interpretable results. One
other possible direction may be incorporating pathway information as another hierar-
chy into the model structure or considering more complicated biological mechanisms
at molecular level, e.g, hidden associations between a gene and other platforms of
the neighboring genes, into the modeling framework, e.g. as considered in [71].
Another possible future extension may be involving histological images of di↵erent
tumor tissue regions as another imaging modality into the study, which will provide
more pathological based interpretable radiogenomic relationships along with relevant
clinical outcomes. We leave these tasks for future work.
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Chapter 3
pathDrive: identification of
pathway-specific upstream genetic
and epigenetic drivers
3.1 Introduction
Cancer is characterized by inter- and intra-tumoral heterogeneity, it occurs when a
group of cells experience a series of molecular alterations enabling them to behave
outside of the control of normal bodily functions. These changes give groups of
tumor cells the ability to grow uncontrollably, metabolize energy in various ways,
evade immune attack, and in advanced cancers the ability to invade neighboring
tissue regions, gain mobility to travel around the body, build and maintain their own
blood supply, and acquire stem cell-like abilities that make them highly adaptable
and equip them with survival and growth advantages over other non-cancerous cells.
While all cancers share some combination of these key hallmarks, each patient’s
cancer is characterized by a unique combination of underlying molecular alterations,
making cancer inherently heterogeneous and thus di cult to diagnose and treat,
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as treatments that work for one patient may not work for others. The challenges
drive current modern cancer research in developing precision medicine which targets
to individualized treatment that involves the application of new diagnostics and
therapeutics, aimed to the necessities of a patient based on his or her own molecular
characteristics [47].
In recent years, many advanced innovative technologies are rapidly enhancing
and expanding the field of precision medicine. These include microarrays and next-
generation sequencing methods that can measure mRNA expression levels, DNA
mutations and copy number changes on a genome-wide scale, as well as proteomic
techniques to measure protein abundances. Given these advanced technologies, more
systematic picture of genomic and epigenomic regulatory mechanisms has been pro-
vided by large-scale and multi-omics profiling of cancers. Furthermore, genomic and
epigenomic data sets such as copy number alteration, mutation, mRNA, methylation,
histone modification and microRNA data sets are all publically accessible via The
Cancer Genome Atlas (TCGA) [108] with advanced tools that have been developed
in quantifying epigenetic and transcriptional factors on a genome-wide scale. It all
leads to the current rapid-developing area of integrative analysis which targets to
analyze heterogeneous types of data from inter-platform technologies, delineating
complicated biological mechanisms at molecular level.
The advent of high-throughput sequencing and profiling technologies has led to
the formation of lists of di↵erentially expressed genes and proteins, leaving new
challenge in extracting main biological meaning from the long lists. Driven by this
particular challenge, researchers focus on partitioning the long lists of individual
genes into smaller groups of related genes or proteins that function in the same
pathways. The pathway gene sets analysis alleviates the complexity in analyzing
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thousands of individual genes or proteins, and more over, it leads to better underlying
biological interpretation in identifying active pathways with particular functional
processes, biological components or structures [54]. Therefore, modern analysis
tends to focus on pathways which can be regarded as more practical units to obtain
functional biological study, given that the silencing of a key gene may not have a
functional impact given the ability of the body to bypass certain molecules and
activate compensatory mechanisms that can achieve the same functional result using
an alternative molecular mechanism. Furthermore, given pathway analyzing and
the advanced sequencing tools, regulation of genes at pathway level that carries out
cellular functions has been recently investigated. Wilk et al., 2017 [116] identifies
specific associations at the systems level in cancer through integrative analysis of
miRNA and overall behavior of the pathways that show functional consequences
of miRNA dysregulation. The trend leads to the study of genetic and epigenetic
regulatory factors that explain inter-patient heterogeneity in particular pathway
activity, elucidating functional biological mechanisms in the molecular processes
underlying specific pathways.
In this Chapter, we develop the pathDrive modeling framework in which we
compute patient-specific measurements of activity for a given pathway from gene
expression and then identify a small number of upstream genetic and epigenetic
regulatory factors that explain the pathway activity. Our main goal is to identify
sparse set of upstream factors that can be regarded as key leverage points or switches
that drive functional activity of a pathway. The selected regulators can be further
explored as potential molecular targets for precision therapy. In this Chapter, we
will describe the general pathDrive model framework outlining how we define and
measure pathway activity levels, methods that we obtain the matched upstream
factors of multiple genomic platforms and the modeling algorithms. In our case study,
45
we apply our framework in identifying potential therapeutic targets in Colorectal
Cancer incorporating its Consensus Moleculary Subtypes (CMS) [33] so as to get
CMS-specific therapeutic targets.
In Section 3.2, we introduce our general methodology flow in pathway score
calculation, upstream factor mapping as well as the modeling framework. In Section
3.3, we illustrate our proposed method on Colorectal Cancer (CRC) CMS-specific
pathway analysis with detailed description of the key pathways characterizing specific
CMS biology and the detection of the genomic and epigenetic switches. Section 3.4
shows the main results and biological interpretation. In Section 3.5, we draw the
conclusions and discussion on some future extensions and advancements.
3.2 Method
In this thesis Chapter, we develop the pathDrive modeling framework in which we
compute patient-specific measurements of activity for a given pathway from gene
expression and then identify a small number of upstream genetic and epigenetic reg-
ulatory factors that explain inter-patient heterogeneity in this pathway activity. In
this way, we utilize genetic pathway analysis to characterize large-scale functional ac-
tivity of a pre-specified molecular process, and then find regulatory factors upstream
to gene expression that are key “leverage points”, or genetic and epigenetic switches
that may be drivers of the functional activity. We will describe the general pathDrive
model, outline how we calculate the pathway activity score, how to collect the up-
stream factors as covariates and the modeling strategy that is used in our framework
to identify potential upstream factors.
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3.2.1 Pathway Score
Gene set enrichment (GSE) analysis provides a framework that focuses on pathway
signature rather than individual gene expression via the generation of enrichment
scores. Current methods in this framework can be generally partitioned into su-
pervised and unsupervised, population and single sample measurements. GSEA
approach described in Tian et al., 2005 [106] is supervised and population based
method that calculates the mean expression for a specific set of genes compared with
those that are out of set. Other relative supervised methods include EPSA [105],
expression pattern analysis [79] and etc. However, in our analyzing framework,
the pathway score needs to be unsupervised and single sample based with specific
summary of the gene pathway activity level for each patient. There are various
algorithms that belong to this category. Pathway Level analysis of Gene Expression
(PLAGE) [109] that utilizes Singular Vector Decomposition (SVD) to obtain a
‘pathway activity level’ that is calculated based on the expression levels of the
genes in the pathway. Also, ssGSEA is another sample-wise enrichment score calcu-
lated through the di↵erence between Empirical Cumulative Distribution Functions
(ECDF) of rank-normalized gene expression of the genes inside and outside the
specific pathway [8]. Combined z-score method computes the mean of the z-score
across all genes within a pathway for each sample after normalization [62]. A recent
study introduced another sample-wise nonparametric unsupervised algorithm called
Gene Set Variation Analysis (GSVA) [35]. This type of pathway score is measured
as a function of the rank-based gene expression of the genes inside and outside the
pathway. According to the study and the simulation results in Hanzelmann et al.,
2013 [35], GSVA, compared with other relative methods, yields in several advantages
such as higher power in detecting subtle di↵erential pathway activities across all
samples and higher survival predictive accuracy.
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Thus, in this Chapter, we chose to apply GSVA as our pathway activity mea-
surement as outcomes, which can be directly calculated from mRNA matrix with
publically available R package named “GSVA” at http://www.bioconductor.org/
packages/release/bioc/html/GSVA.html. However, the outcome of our pathDrive
analysis can be applied using any subject-specific pathway score based on biological
context and purpose.
3.2.2 Genomic and Epigenomic Factor Mapping
A crucial aspect of pathDrive is specification of an appropriate set of potential
upstream genetic and epigenetic regulatory factors. For a given pathway, we consider
potential upstream regulatory factors summaries of mutation, copy number, and
CpG methylation for any genes present in the pathway, plus expression levels of any
miRNA or transcription factors (TF) associated with any pathway genes. Therefore,
our multiplatform genomic data sets are expressed as data matrices: XmRNA, XCN ,
XmiRNA or XMethy and XMutation, each with rows as samples and columns as genomic
features (either gene level summaries or matched sites) of the respective platforms.
The terms in the model are described and interpreted in details as follows, for
gene g,
• XmiRNAg is an aggregated miRNA expression value matrix that integrates infor-
mation across microRNAs that have been documented to regulate the expression
of gene g. For a given gene, there exists multiple microRNAs that interact with
this gene. Several mRNA-miRNA membership matrices provides us the map-
ping references, e.g. targetHub [69], which collected miRNA-mRNA interaction
records based on 5 external databases, multiMiR [69] is generated based on
14 external databases, including validation databases, prediction databases and
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drug-associated databases. Here in our thesis Chapter, we apply targetHub in
our mRNA-miRNA mapping, and for a specific gene, we include all the mapped
microRNAs into covariate matrix that we incorporate into our model.
• XCNg are gene-level summaries of the CN alteration for the gth gene with di-
mension NG ⇥ CNg. Similarly, as there are multiple CN alteration values from
di↵erent markers within the same gene, CNg denotes the number of gene-level
vectors. In our model, we include copy number alterations that are measured
as the average copy number within the specific gene region.
• XMethyg contains matched CpG sites values for gene g. Since simple gene-
level summaries such as mean methylation across all CpG results in limited
biological interpretation, here we applied Gene-Specific Methylation Profiles
(GSMP) devloped in Liu et al., 2017 (submitted) which identifies a small tissue-
specific set of functionally relevant CpGs (typically 5-10) whose methylation
values significantly predict expression for each gene in the genome. It considers
the complexity of the measurement of methylation given the following biological
factors: (1) CpGs within gene body or up to 500kb upstream or downstream of
the gene can be relevant described in Aran et al., 2013 [5]; (2) there are a large
number of potentially relevant CpG sites per gene (median across genomes of
248/gene on 450k methylation arrays, referred to Liu et al., 2017 (submitted));
(3) only a small subset of CpGs are expected to be functionally relevant in
particular gene/tissue context; (4) which CpG are functionally important varies
across tissue types [53]. Thus, our pathDrive model includes the potential
methylation beta values for any CpG in the GSMPs of any pathway genes or
associated transcription factors as part of the upstream factor covariates.
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• XMutationg is the mutation of gene g, which contains summaries of mutation
(1=mutation in gene body, 0 none). To obtain su cient information, we filter
out the mutations which have smaller than 2% frequency.
3.2.3 pathDrive Modeling
For each pathway, suppose the GSVA score values for n subjects can be expressed
as Y with the dimension n ⇥ 1 and the pathway gene set contains m genes, each of
the element Yi 2 [ 1, 1]. For each gene, we match corresponding di↵erent platform
data sets as described above. The upstream factor matrices were then combined in
categories, denoted as : X = {XCN , XMethy, XmiRNA, XMutation}, which forms the
entire genomic upstream factor matrix that is regarded as covariate/design matrix
in the modeling part.
Thus, to quantify the relationship between pathway score and upstream regulatory
factors, we consider linear regression model that can be expressed as Y = X  + ✏
and ✏ ⇠ N (0, I 2). Given the high dimensionality and the assumption of the
sparsity, a proper feature selection algorithm need to be selected, which leads to
high prediction accuracy and the interpretability of regression model. There are
di↵erent variable selection methods such as Ridge Regression [43] which contains l2-
norm regularization term in the linear regression estimation, LASSO (least absolute
shrinkage and selection operator) [107] which contains l1-norm regularization term,
Elastic Net [124] which can be viewed as the combination of ridge regression and
LASSO. Other Bayesian shrinkage methods in variable selection can also be consid-
ered, such as spike-slab prior which has been widely applied with good theoretical
properties [52] [98], Bayesian shrinkage methods with Global-local priors including
normal gamma prior [88], Dirichlet Laplace [13] and etc. Technically, we can apply
any of the methods for variable selection, however, considering about the simplicity
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and e ciency, we chose to apply LASSO that performs both variable selection and
regularization. Moreover, considering the consistency of variable selection, at the
same time, we incorporate stability selection as developed by Meinshausen, Nicolai
and Bu¨hlmann, Peter [73]. The stability selection approach imbeds sub-sampling
technique into high dimensional variable selection algorithms as in our context
LASSO, which has been proved to have several attractive properties in Meinshausen
et al., 2010 [73], such as selection consistency, depends little on the initial regulariza-
tion parameters, and better multiple -testing error control.
More specifically, at each stability selection iteration, a random subsample of
1, 2, 3, ..., n of size n2 is drawn from the entire sample set without replacement. Then,
LASSO modeling is processed based on the subsample set, that is, regularization
parameter   is tuned via cross validation and the final   together with the selected
features are extracted. We repeat the same process for S times and calculate the
selection probability for each covariate. The ones with probability larger than
50% are regarded as significant in a↵ecting the pathway activity. Our final linear
regression model will be estimated only using the significant features with the whole
sample set, and the R2 is computed for model evaluation. Moreover, as we also
target to evaluate the performance using stability Lasso, we measure the concordance
correlation coe cient [60] based on 5-fold cross validation across the entire samples.
We apply the methodology and evaluation framework for each pathway gene sets
that we target, and summarize the results including evaluation measurements such
as R2 and concordance correlation coe cients, and the selected pathway drivers.
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3.3 Application
Our methodology can be broadly applicable to any cancer types, but it is initially
applied to two important gastrointestinal cancer types: Colon (COAD) and rectal
(READ) cancers. As we combine these two cancer types into one group, it has been
defined as colorectal cancer (CRC). Moreover, the biological information that can be
incorporated into the analysis is Colorectal Cancer Consensus Molecular Subtypes
(CMS) that is studied in Guinney et al. 2015 [33]. Our goal is to identify genomic
and epigenetic upstream factors that can be regarded as potential therapeutic targets
for key pathways that characterize CMS subgroups. We discuss pathway selection,
CMS groups and modeling results in our application section.
3.3.1 CMS groups
Colorectal cancer is the third most common cancer type and a leading cause of can-
cer death worldwide. Guinney, et al., 2015 [33] assembled the colorectal subtyping
consortium (CRCSC) and identifies consensus molecular subtypes (CMS). This was
done by assembling a data base of gene expression measurements from 4,151 CRC
patients from an international collection of 18 studies, having each of the six sub-
typing systems applied to each of these samples, and then using a network analysis
to identify consensus clusters. From this analysis, we introduced a system of four
consensus subtypes with distinct biological characteristics: CMS1 (Immune, 17.5%)
is characterized by enrichment in hypermutation, hypermethylation, microsatellite
instability (MSI), and immune activation. CMS2 (Canonical, 42%) demonstrates
canonical CRC characteristics including epithelial di↵erentiation, MYC and WNT
activation, and high levels of chromosomal instability. CMS3 (Metabolic, 13%) is
epithelial and showed high levels of metabolic dysregulation, with higher rates of
KRAS mutation. CMS4 (Mesenchymal, 27.5%) shows characteristics of epithelial
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mesenchymal transition (EMT), activation of TGF-, angiogenesis, and prominent re-
active stroma. Thus, we incorporate this information into the analysis of pathDrive
in CRC, detecting important pathways with their activity significantly di↵erentiating
the 4 subtypes and delineating the pathway molecular switches that influence the
selected pathway activity.
3.3.2 CRC validation data sets
Three gene expression data sets are used to obtain the commonly important path-
ways, which are: CRCSC Gene Expression Data, MDACC Integromics Colorectal
Cancer Data and TCGA Colorectal Cancer Data. Using these three data sets, we
pre-select the important pathways with their scores that significantly di↵erentiate
the CMS groups as described above. Below we further describe the data sets in details.
CRCSC Gene Expression Data
This is a gene expression data set from A↵ymetrix arrays from 1500 subjects
and 13 studies that were part of the CRCSC data set.
MDACC Integromics Colorectal Cancer Data
The in house clinical collaborators have routinely banked primary tissue sam-
ples from M.D. Anderson patients and obtained a similar panel of multi-platform
genomic measurements as those that are collected by TCGA. The current data
set consists of 261 primary colorectal cancer resection speciments, collected from
2001-2009 and predominantly stage 2 and 3 with some stage 4. All samples had
frozen tissue stored and gene expression measured by Agilent microarrays used as
part of the CRCSC cohort. Additionally, these samples have been subjected to
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intensive interrogation through a variety of genomic platforms including whole exome
DNA sequencing, RNAseq, copy number measurements, 450k methylation arrays,
miRNA and other non-coding RNA, and RPPA protein arrays, amongst others.
These have been processed in house by faculty in the Department of Bioinformatics
and Computational Biology in an analogous manner as the TCGA data.
TCGA Colorectal Cancer Data
The Cancer Genome Atlas (TCGA) is a public cancer genomic data set, de-
rived from a project, aiming to provide more comprehensive information of human
cancer genomes by creating an “atlas” of high-throughput multiple genomic profiles
across multiple cancers, was launched in 2005 as a publicly funded project [108].
This worldwide initiative involves the study of 32 cancers, and each cancer has
on the order of several hundreds of samples for which each genomic, epigenetic,
and proteomic platform was implemented. Samples were preprocessed and batch
corrected in a common way in Genome Data Analysis Centers, of which M.D.
Anderson was one, and the data was made publicly available through in house
portal “http://bioinformatics.mdanderson.org/TCGA/gsresults/”. Colon (COAD)
and rectal (READ) cancers were two of the types, and between the two of them we
have a total of 604 patient samples with whole exome mutation, copy number, 450k
methylation array, RNAseq, miRNA panel, and reverse phase protein arrays (RPPA)
measurements.
3.3.3 Target Pathway Gene Sets
In our analysis, the pathway gene sets were browsed and downloaded from Molecular
signatures database (MSigDB) [67], which is a public online resource that contains
the largest number of annotated gene set collections for Gene Set Enrichment
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Analysis (GSEA) [67] with the website http://www.broadinstitute.org/msigdb.
MSigDB contains 8 major collections based on established biological processes, states
or cancer oriented gene expression studies.
We chose to focus on the following gene sets which are typically studied in the
GSEA literature. The pathway gene sets collections that we focused on are Biocarta,
Genomic Locus, Hallmark Collection, KEGG Pathways, Oncogenic Signatures, Re-
actome Pathways. The number of the member gene sets within each collections
are listed as follows: BIOCARTA: 217, HALLMARK: 50, KEGG: 302; Onco-
genic Signatures: 189; REACTOME: 674; Genomic Locus: 326. The membership
genes matching to each gene set could also be downloaded from MSigDB [67], which
could be further analyzed both for pathway analysis or search for matched upstream
factors.
With the computed GSVA pathway scores for each pathway and each subject
respectively from MDACC, TCGA, and CRCSC data sets, our “target pathways”
were extracted based on the criterion that if the pathway could significantly di↵er-
entiate the consensus molecular subtypes (CMS) of colorectal cancer according to
the calculated statistical tests. Thus, the pathway is defined being characteristic if it
satisfies the following criteria:
• The ANOVA p-value of the GSVA score for comparison across all CMS groups
is significant after adjusting for FDR ( FDR < 0.05)
• For that CMS, the mean GSVA score is either highest (characteristic high) or
lowest (characteristic low) across the 4 CMS.
• The pairwise GSVA comparison of that CMS group vs. all 3 other groups is
small (< 0.05 unadjusted)
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The final list of the target pathway gene sets are the ones which passed the above
criterion with at least 2 data sets (MDACC, TCGA and CRCSC A↵y). Our pathDrive
model will only be established with these pathways in our further analysis.
3.4 Results
3.4.1 Overall Result
Based on the criteria we select important pathways, below we summarize the number
of the targeted pathways with the pathway score significantly remain the largest
and smallest respectively for CMS1, CMS2, CMS3 and CMS4. More specifically, for
example, for CMS1, we calculate the number of the pathways that have pathway
score the highest and the lowest with significant di↵erence for CMS1 group compared
with others and significantly di↵erent in pairwise comparison as well. The following
Figure 3.1 shows the corresponding summary. It illustrates that CMS4 group has
the largest number of the important pathways, while CMS3 has the smallest.
Figure 3.1: Summary of the number of the targeted pathways for each CMS group
We apply the methodology framework to each important pathway for CMS groups,
and overall, we achieve comparatively sparse set of the predictors that are selected
to significantly a↵ect the pathway score. Figure 3.2 illustrates the percentage of the
predictors that are selected for each pathway gene sets respectively for each CMS
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group with histogram. The right skewness and the small value of the percentage
indicate sparsity with CMS3 pathways selecting more sparse upstream factor subsets.
And the percentage for the entire pathways is also shown in Figure 3.3. Given the
sparsity, we show that the variance of the pathway activities that are explained by
the spase sets are in general high enough to implicit the parsimonious, that is, we
calculate the R squared for training set (entire data set) and Figure 3.4 shows its
histogram. Moreover, we do 5-fold cross validation to test the stability and compute
the concordance correlation coe cients for each pathway and the histogram is shown
in Figure 3.5. Thus, it shows that for some pathways, our methodology successfully
achieved our goal in detecting the ”leverage points” that explain enough variance of
the pathway activities. And we further explain the results for some specific targeted
pathways in details with biological interpretation in Section 3.4.2.
Among the selected genetic and epigenetic factors, the proportion of di↵erent
platform respectively for each CMS group is shown by pie-chart in Figure 3.6. The
results show that Methylation and microRNA in general, comprise the large propor-
tion of the selected factors, which is reasonable given our construction of the potential
upstream factors, that is one gene has one corresponding copy number alteration
and one mutation status, however, it can be mapped with multiple microRNA and
Methylation CpG sites. The percentages for overall pathway gene sets are shown in
Figure 3.7.
3.4.2 Specific Results and Biological Interpretation
Here in this section, we extract some modeling results of some typical and represen-
tative pathway gene sets respectively for CMS groups. We summarize the results
from the following aspects: number of the genes in the pathway, heatmap of the gene
expression with pathway scores, modeling results with visualized plots and biological
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Figure 3.2: Histogram of the percentage of the number of the selected predictors for each
CMS group based pathways
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Figure 3.3: Histogram of the percentage of the number of the selected predictors for all
targeted pathways
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Figure 3.4: Histogram of the R2 estimated by the selected features of pathDrive modeling
for all pathways
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Figure 3.5: Histogram of the concordance correlation coe cients estimated by the selected
features of pathDrive modeling for all pathways
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Figure 3.6: Pi-chart of the percentage of the upstream factors for each platform and for
each CMS related pathways
Figure 3.7: Pi-chart of the percentage of the upstream factors for each platform and for
all targeted pathways
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interpretation.
REACTOME INTERFERON GAMMA SIGNALING
Results:
This signaling pathway belongs to REACTOME collection with 59 membership
genes, it is selected as the important pathway that significant has the highest path-
way activity in CMS1 compared with that of other groups, which has been validated
by our 3 data sets (CRCSC A↵y, TCGA and MDACC), as shown by the boxplot in
below.
Figure 3.8: Boxplot of GSVA scores across 3 datasets and across CMS groups (REAC-
TOME INTERFERON GAMMA SIGNALING )
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The mRNA heatmap with samples sorted by GSVA score and clustered by genes
illustrated in Figure 3.9 provides us visualized perspective of the score measurement
of the pathway activity, it is clear that the ones with higher GSVA score, in general,
tend to have higher mRNA values for most of the genes. Moreover, based on the CMS
group label, we can conclude that CMS2 subpopulation tend to have low pathway
activity while the CMS1 subpopulation having comparatively higher pathway activity.
Figure 3.9: Heatmap of gene expression and GSVA score with samples sorted by GSVA
score (REACTOME INTERFERON GAMMA SIGNALING )
Totally 8 predictors are selected with table showing the selection probability, mag-
nitudes, and marginal correlation with the pathway score listed in Figure 3.10.
Regarding with the predictor names, “M ” represents the methylation factors. Thus,
there are 7 methylation sites that are selected as the switches and 1 microRNA.
Among all 8 predictors, “M HLA.DQA2 cg11706729” has the highest selection prob-
ability and is negatively correlated with the pathway score. If we further check if this
predictor significantly di↵erentiates the CMS groups, we compute its corresponding
anova p value as smaller than 0.05 with violin plot shown in Figure 3.11. Moreover,
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we checked the model performance by measuring its R2 and concordance correlation
coe cient with scatter plot showing the exact pathway score values as well as the pre-
dicted values as shown in Figure 3.12. The high R2 and CV CCC values indicate that
our model predicts well and yield to great parsimonious given the sparse predictor set.
Interpretation: Study shows that Interferon-signaling pathway has important
impact on colon and rectal cancer types in their risk and survival due to its genetic
variation [100]. Methylation site cg05141234 is selected as upstream factor mapped
with genes HLA.DPA1 and HLA.DPB1. HLA gene family functions in forming group
of related proteins named human leukocyte antigen (HLA) complex that helps the
immune system in the body. It has been reported that the member gene HLA.DPA1,
with the changes in gene expression, is likely to be one of the representatives in
causing colon adenocarcinomas [97]. Methylation site that is associated with gene
OAS3 is also selected to be important. Study has demonstrated that OAS with
full name oligoadenylate synthetase that regulates ribonuclease L and PKR (protein
kinase R) and with the regulated RNaseL and PKR being found to be among several
IFN-induced genes that attribute direct in vivo antiviral activity [95]. Two methy-
lation CpG sites related with gene STAT1 significantly and negatively influences
the pathway activity. Study shows that the STAT1 gene which belongs to Signal
Transducers and Activators of Transcription (STATs) family has been found to have
decreased expression levels in transformed intestinal epithelial cells in colorectal
cancer [57]. Moreover, this finding consists with STAT1’s tumor suppressor nature.
The microRNA miR.1296 has been recently discovered to serve as tumor suppressor
role in a subtype of breast cancer [91], and also found to be prognostic for distant
metastasis-free survival (DMFS) in T2-T3N0 colon cancer [15].
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Figure 3.10: Selected upstream factors and their selection probability, coef-
ficient from OLS model and marginal pearson correlation for pathway REAC-
TOME INTERFERON GAMMA SIGNALING
Figure 3.11: Violin plot of the methylation HLA.DQA2 cg11706729 across CMS groups
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Figure 3.12: Scatter plot of the prediction performance for pathDrive modeling (REAC-
TOME INTERFERON GAMMA SIGNALING)
3.5 Shiny App Application
We established an interactive web app “Shiny App” to illustrate the results, simulta-
neously, this App provides people a way to retrieve their interested pathways, the
general pathway properties, as well as specific pathDrive modeling results. The
App could be accessed under http://qcprpudev6:3833/pathDrive_YZhang/, and
for Colorectal Cancer, people can target di↵erent pathway collections, their proper-
ties in di↵erentiating CMS groups. For each pathway, the following list shows the
items that could be retrieved.
• Membership genes that belong to the pathway
• Heatmap showing mRNA and GSVA scores labeled with CMS groups, the sam-
ples are sorted based on GSVA scores.
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• Boxplot showing GSVA score for di↵erent CMS groups for 3 data sets (A↵y,
TCGA and Integromics)
• Scatter plot showing predictive accuracy with R2 within training set and 5-fold
cross validation concordance correlation coe cient.
• Table of the selected upstream factors, their selection probability, coe cient
and marginal correlation with GSVA score.
• For each selected upstream factor, it can lead to its violin plot for di↵erent CMS
groups with ANOVA test being implemented. And the pathways that select this
factor are also listed in a table.
3.6 Discussion
Our pathDrive framework provides novel biological formulation in identifying a
sparse set of regulatory factors that influence pathway activity that is measured
based on gene expression levels. By detecting the key genetic and epigenetic switches
that may be the potential drivers of the functional activity, our proposed framework
has several key advantages: (1) our model involves pathway level measurement as
response rather than individual gene level summaries, which describes higher level
representative of the biological process; (2) the formulation accounts for the natural
information flow of DNA ! mRNA ! protein regulated by genetic and epigenetic
factors; (3) the framework incorporates latest multiplatform genomic factors as
potential regulators; (4) the modeling part utilizes e cient and interpretable feature
selection algorithm. Although we mainly applied our methodology into the case
study in colorectal cancer types with 4 subtypes, our method framework is general
and can be directly applied into other disease domain with pathway score generated
and calculated from the corresponding gene expression and upstream factor matrix
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aggregated from their multiplatform genomic data profiles.
We applied our methodology framework into the analysis CRC with 4 CMS groups
incorporated into the study. Important pathways that significantly di↵erentiate
the CMS subgroups were selected, and for each, we model the relationship between
pathway score and the genetic and epigenetic factors. Result shows that parsimonious
could be achieved in that sparse set of the predictors were selected that can explain
large variation of the pathway score for most of the pathways. Moreover, results for
some specific targeted pathways that were also illustrated, such as pathway Hallmark
INF-↵ Response, Reactome INF-↵/  signaling, Reactome INF signaling and etc. For
example, for Reactome INF-  signaling pathway, factors M HLA.DQA2 cg11706729,
M STAT1 cg03110996, M STAT1 cg00676801, miR.1296 and etc. with some of the
factors selected and visualized and based on literature review, M STAT1 cg03110996
lies in CpG shore within promoter region, it functions as active enhancer. It has
been demonstrated that STAT1 has prosurvival e↵ects on KRAS colon cancer cells
by regulating pathways that initiate mRNA translation. Other important pathways
for CRC were summarized with interactive Shiny App as discussed in Section 3.4.3.
To summarize our study, we establish a general pathDrive modeling framework,
outline the pathway score calculation, upstream factor formulation, modeling strat-
egy as well as results interpretation. We applied our framework to identify potential
CMS-specific therapeutic targets, obtained the results for overall targeted pathways
and for some specific pathways. Our findings o↵er potential drug discovery biomarker
targets and can be further investigated in the future biological experiment and anal-
ysis. Our Shiny Application provides a useful tool for biologists/bioinformaticians in
our result searching with more user-defined and convenient interface, which facilitate
further investigation and research in this area.
69
We admit that our analyses yield to multiple limitations. From data prepro-
cessing perspective, the selection of miRNA to include in the model was implemented
using an unsupervised approach based on targetHub [69] rather than a supervised
approach checking directly at mRNA-miRNA correlation in our data sets. From
modeling perspective, we only presented results using the LASSO for feature selec-
tion. As mentioned in Section 3.2.3, technically, we can apply any well-established
feature selection algorithms, however, here in this thesis chapter, we do not include
the implementation of model comparison based on our real data sets. Implementing
di↵erent models and doing comparison evaluated by multiple predictive criteria will
be left to future work.
Several possible future directions could be explored based on our proposed frame-
work. One direction could be including the complicated interaction terms between
di↵erent platforms or within each platform into the model, such as interaction
between neighboring methylation CpG sites, microRNA and etc. Another possible
advancement may be incorporating nonlinearity in the relationship modeling which
allows more flexibility. One other direction may be exploring more statistical models
and summarizing the selection and prediction results with ensembling methods. We
leave these tasks for future work.
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Chapter 4
BLINK: Bayesian Linked
Regression Models for Pan-Cancer
Genomic Data Integration
4.1 Introduction
Rapid development in genomic technologies and worldwide collaboration in generat-
ing comprehensive and diverse genome-wide database, such as The Cancer Genome
Atlas (TCGA) [108], motivate integrative analysis of multi-dimensional molecular
profiles within and across tumor types. These analyses aim to delineate hidden
associations among di↵erent genomic platforms, and with clinical characteristics.
Besides the high throughput genomic data sets available, more comprehensive study
eager to involve the analysis of protein expression data. Given that protein levels,
which contain complex genomic and transcriptomic aberrations with translational
and post-translational regulation, can hardly be investigated merely through the
analysis of genomic and transcriptomic, the reverse-phase protein arrays (RPPA),
a quantitative antibody-based technology, has been applied in functional protein
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analysis. With this advanced technology, people have brought in a high-throughput
proteomics database of the samples from TCGA, which is publically available through
the Cancer Proteomics Atlas (TCPA) [66].
Given the availability of high-quality genomic and proteomic data sets, more
comprehensive analysis including correlation studies between protein levels and other
genomic related profiles, have been implemented: e.g, Akbani et.al [4] shows relatively
high correlation between protein and mRNA on HER2; Zhang et.al [121] discovered
that protein level, measured through PI3K/AKT/mTOR pathway activity, was
found to be associated with mutations or copy alteration. Thus, our initial interest
lies in finding upstream transcriptomic and genomic drivers that a↵ect proteomics,
so as to elucidate underlying biological protein regulatory mechanisms for a specific
cancer type. Furthermore, study shows that analyzing proteomic processes with
upstream transcriptional factors across di↵erent tumour types is of great necessity
compared with disease-specific studies which may neglect potential commonalities
and di↵erences in molecular mechanisms. And recent studies demonstrate the exis-
tence of this commonality, e.g, Milewska et. al [74] found that 12% of their cancers
have ERBB family somatic mutations based on the analysis of more than 14,000
patients. Thus, our further interest lies in detecting the upstream transcriptomic and
genomic factors that drive proteomic processes for di↵erent cancer types. However,
e↵ective signal detection problem lies in that rare cancer types do not have enough
sample size, while common cancers, with comparatively larger sample sizes, tend to
have stronger power for signal detection. With this unbalanced sample size issue and
the existing commonality discovered in genomic drivers, in this Chapter, we target
to detect genomic upstream proteomic drivers for multiple cancer types, borrowing
strength of the signals from common cancers to rare cancers based on their hidden
commonality/similarity of the regulators, that improves the sensitivity and specificity
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of the signal detection, and at the same time, promotes the learning of the similarity
in molecular mechanisms across di↵erent cancer types.
Given biological problem as described above, statistically, our goal is to charac-
terize key covariates that influence the responses for multiple strata while borrowing
strength from the similarity structure inferred by the common covariates that are
shared across strata. The regression stratum can be of di↵erent forms, such as gender,
nationality, race and etc. In our case study, we take cancer type as the stratum. Clas-
sic approach for allowing covariates to vary across strata is through the formulation
of a large single regression with the introduction of interaction terms among multiple
strata [3]. However, this approach does not give a global sense of the similarity in
the selected covariates among strata, and the interaction lies in coe cient estimates
rather than in covariate selection. Another common way people address the problem
is to apply separate model inference procedure for each stratum. However, for rare
cancer, this approach will consequently lead to low sensitivity or specificity due to
lacking of enough sample size. And the approach neglects the study of potential
similarity among covariates across the strata. When considering borrowing strength,
alternative common way is to implement the inference with large pooled data that
integrates all strata samples. However, this approach results in high false positive
rate due to overly borrowing strength especially for strata that are not similar in their
true signal structure. Therefore, we mainly consider adaptively borrowing strength in
covariate selection across multiple strata through some sort of “correlation” which can
be implemented in di↵erent ways. One could utilize Seemingly Unrelated Regression
(SUR) [120] model where they improve parameter estimation e ciency by borrowing
strength through contemporaneous cross-equation error correlation and later has
been extended to Sparse seemingly unrelated regression (SSUR) [111] that can be
applied into high dimensional cases. However, both of them are limited in direct
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borrowing strength for signal detection and exploring its selection similarity. Another
approach that can be applied is through the correlation in magnitudes. That is, ba-
sically, when stacking the multiple strata equations on top of each other as shown in
Equation (1), the entire system can be regarded as a large single regression problem,
to borrow strength, people can apply di↵erent grouped shrinkage methods such as
grouped lasso [119], normal gamma shrinkage prior [32], horseshoe prior [19] and etc.
for possible related covariates. However, such an approach can be limited in allow-
ing the flexibility for the stratum-specific coe cients to vary in signs and magnitudes.
In this Chapter, we developed novel Bayesian linked regression modeling frame-
work to the problem of variable selection for multiple strata. The linkage lies in
the probabilities of covariate indicators, which is learnt via a Markov Random Field
(MRF) prior [65]. This specific prior encourages the selection of a covariate for the
regression given the same covariate is detected in related regressions. Unlike the
aforementioned approaches, the regression relatedness is imposed and learnt from
signal detection aspect, more specifically, higher relatedness or similarity indicates
more common selected covariates. This pairwise relatedness is learnt and modeled
by putting a spike-and-slab prior on parameters that represent the similarity mea-
surements, with their inclusion posterior probabilities indicating the corresponding
pairwise strata similarity. To detect stratum-specific signals, we borrow strength
of the relatedness by incorporating the similarity parameters into MRF prior set-
ting, allowing adaptively sharing information between strata. Moreover, we also
formulate variable-specific informative inclusion prior probability that encourages
proper sparsity. Our proposed framework allows adaptively borrowing strength
across related strata and infering their relatedness from common signals. In our
simulation study, we demonstrate the advantage of our model in that it leads to
better variable selection performance compared with other alternative approaches,
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and the capability of learning the similarities. We find higher accuracy in variable
selection especially for strata with relatively small sample sizes and with high
hidden similarity linkage with other strata regressions. Finally, to illustrate our
methodology, we implement an integrative grouped pan-cancer analysis in detecting
driving genomic and transcriptional upstream factors that characterize RPPA based
proteomic pathway activities, and simultaneously inferring which cancers in our
group share more common proteomic regulative drivers for a specific pathway.
The rest of the thesis Chapter is organized as follows. We introduce our Bayesian
linked regression model framework in Section 4.2 including formulation, similarity
structure and prior settings for the main parameters and hyperparameters. Posterior
sampling and Model selection will be presented in Section 4.3. The simulation results
are demonstrated in Section 4.4 and the application of real pan-cancer integrative
analysis is described in Section 4.5. We conclude this thesis Chapter with brief
discussion in Section 4.6.
4.2 Statistical Model and Methods
Figure 4.1 illustrates the general flow of our modeling framework. Our joint model
mainly contains two levels: Regression Level and MRF Process Level. The first level
involves linear regression models with specific prior settings for the corresponding
coe cients. The second level denotes the similarity parameters that link the models
defined in the first level, and establishes the prior settings for the similarity parame-
ter matrix that could be inferred from the joint model. The specific model settings,
parameter definitions, prior and posterior distributions, and the model selection com-
ponents are described in the following subsections.
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4.2.1 Model at Regression Level
Our goal is to analyze key covariates that a↵ect the dependent variable across multiple
strata. More explicitly, suppose we construct a linear regression problem with K
di↵erent strata. Thus, considering a single observation and a stratum, the model can
be expressed using the form
yki =
j=PX
j=1
xkij kj + ✏ki, k = 1, 2, ..., K; i = 1, 2, ..., nk; j = 1, 2, ..., P (4.1)
where yki denotes the ith observation for the kth stratum, which is to be linearly
explained by the covariates with the total number represented as P . Our method-
ology framework deals with the cases where we consider same regressors, in their
variable types, but not their actual values. However, we allow di↵erent sample sizes
for di↵erent cancer types. xkij is the jth predictor of the ith observation for the kth
stratum, the corresponding coe cient is denoted as  kj. ✏ki is the random error
component of the ith obervation for kth. K is the total number of the strata. nk
denotes the sample size for the kth stratum.
The K strata can be separately expressed as the above equation, forming to-
tally K equations. However, to be more explicit, the K equations could be compactly
expressed as
266666666664
y1
y2
y3
...
yK
377777777775
=
266666666664
X1 . . .
X2 . . .
X3 . . .
. . . . . . . . . . . . . . . . . . . . . .
. . . XK
377777777775
266666666664
 1
 2
 3
...
 K
377777777775
+
266666666664
✏1
✏2
✏3
...
✏K
377777777775
(4.2)
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To estimate the coe cient vector   = { 1, 2, ..., K}, di↵erent mechanisms to bor-
row strength across multiple regressions could be applied. One can apply SUR model
by incorporating the inter-correlation in error vectors ✏ = {✏1, ✏2, ..., ✏K}, which leads
to comparatively higher parameter estimating e ciency. However, this approach does
not directly borrow strength from variable selection aspect and has the limitation
of detecting the common variables that are selected by di↵erent strata regressions.
Another common way is to borrow strength via the correlation of the magnitudes,
which limits the flexibility in their signs and magnitudes. However, our model bor-
rows strength via variable selection indicators across the regressions while allowing
flexibility in coe cients, and adaptively detects the similarity of the selected features.
In our case study, Xk represents the covariate matrix with dimension nk ⇥ P
where nk denotes the sample size for cancer type k, and P is the total number of the
predictors that are included all across the cancer types. yk represents RPPA based
pathway activity score for cancer k, and Xk comprises the corresponding mRNA,
methylation, copy number and microRNA factors matching with the genes belonging
to that pathway. Our main goal is to select key molecular upstream factors that
a↵ect RPPA based pathway activity while borrowing strength across K cancer types
and assessing the similarity in their signal selection simultaneously. More details of
the application are described in Section 4.5.
4.2.2 Linking Regression via Markov Random Field Process
Considering a simple regression model for each stratum as described in Equation (1),
our key target is to detect the significant covariates as mentioned in the introduction.
To implement variable selection, we adopted the Bayesian “spike and slab” approach
[75] [29] which defines a binary latent variable  kj 2 {0, 1} for each coe cient param-
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Figure 4.1: General modeling flow: Models at Regression level with K strata, each with
coe cient vectors which are inferred by variable selection indicators; Markov Random Field
Process incorporates the linkage of the indicators through similarity matrix denoted as ⇥,
with each elements inferred from similarity indicator Matrix.
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eter  kj as illustrated in Figure 4.1. In this particular framework,  k depends on  k
with each element independently following conjugate Gaussian mixture priors:
 kj ⇠ (1   kj) 0 +  kjN (0, c 2k) (4.3)
where  0 represents a point mass at zero. Residual variance  2k follows Inverse Gamma
prior which is conjugate:
 2k| k ⇠ InverseGamma(e/2, ef/2) (4.4)
and c represents a scalar that could be adjusted based on the magnitude and the
sparsity of the signals.  kj follows a certain distribution that will be mainly discussed
in the following sections. With the prior distribution, the entire variable selection
procedure is then implemented based on stochastic search over the marginal posterior
space where  k|Y 2 {0, 1}P .
In stead of individually assigning Bernoulli prior for each selection indicator vector  k
, in our approach, we link the multiple strata regressions by introducing dependence
among each  j , which takes the vertical direction of  k across K regressions. More
specifically,  j denotes the selection indicator vector across K strata for the jth
predictor. To impose the selection dependence/linkage for each predictor, in our
approach, we set up MRF prior on through the application of MRF prior settings on
 j . The particular prior was originally established and applied in Bayesian variable
selection in linear regression context [65] based on the assumption that the covariates
lie in an undirected graph, and with the hidden structure of the covariate matrix
incorporated into the framework. The MRF prior that we developed acts similarly
wherein we incorporate the structure for each variable across multiple regressions
allowing similar strata select similar covariates. Moreover, the MRF prior was
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applied and implemented in linking multiple graphs by Peterson et al., 2015 [90] and
has been demonstrated having proper properties.
Specifically, consider one predictor j, the prior probability that we assign to
the indicator vector  j can be expressed as:
p( j |⌫j,⇥) = C(⌫j,⇥) 1exp(⌫j1T j +  jT⇥ j) (4.5)
where 1  j <= P denoted as the jth predictor,  j denotes the latent inclu-
sion indicator of the jth variable across K strata regressions. 1 represents the
unit vector with dimension K, ⌫j represents the same variable specific parameter
across K, ⇥ denotes the symmetric matrix with dimension K ⇥ K representing
the similarity among covariate selection across K regressions. More specifically,
matrix ⇥ is o↵-diagonal matrix with each element representing the pairwise simi-
larity as magnitude in terms of the variable selection of the corresponding regressions.
More specifically, based on the MRF prior, the normalizing constant is denoted
as C(⌫j,⇥) where
C(⌫j,⇥) =
X
 j2{0,1}K
exp(⌫j1
T j +  j
T⇥ j) (4.6)
If there for all strata regressions, no features are selected, the prior probability be-
comes
p( j = 0|⌫j,⇥) = 1
C(⌫j,⇥)
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Specifically, given the prior, the inclusion probability of the jth predictor for the
kth regression given the inclusion of the jth predictor in the remaining regressions is
p( kj|{ mj}m 6=k, ⌫j,⇥) =
exp( kj(⌫j + 2
P
k 6=m ✓km mj))
1 + exp(⌫j + 2
P
m 6=k ✓km mj)
(4.7)
4.2.3 Variable Selection Structure Similarity
⇥ denotes the selection similarity matrix, representing how similar two regressions
perform in terms of selecting the same variables, if considering two strata, more
variables that are selected by both of them leads to higher similarity. The elements in
this nonzero o↵-diagonal matrix represent the magnitude of the pairwise similarity.
In our analysis, the similarity matrix is inferred from data. Considering the fact
that two strata may have similar driving predictors at di↵erent levels, or not having
any common ones, the similarity matrix needs to be flexible enough to handle the
exisitence of the similarity and the magnitude. Driven by this motivation, we place
a spike-and-slab prior on each element of ⇥, denoted as ✓km, by introducing a corre-
sponding latent indicator matrix T , with each element denoted as ⌧km, as illustrated
in Figure 4.1. To e↵ectively represent the similarity, ✓km needs to be either zero,
or positive, to induce the better discrimination of zero and positive values, we put
Gamma(↵✓,  ✓) distribution when ↵✓ > 1 as the ’slab’ portion of the spike-and-slab.
Johnson et al., 2010 [51] described the performance in model selection when putting
nonlocal prior in details.
The latent variable ⌧km represents if regression k and regression m are related
in terms of selecting common features. The mixture prior for element ✓km can be
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written as
p(✓km|⌧km) = (1  ⌧km) 0 + ⌧km  
↵✓
✓
 (↵✓)
✓↵✓ 1km e
  ✓✓km (4.8)
where ↵✓ and  ✓ are fixed hyperparameters. The binary latent variable ⌧km is given
independent Bernoulli prior distribution
p(⌧km|w) = w⌧km(1  w)1 ⌧km (4.9)
where w denotes a fixed hyperparameter with value lies in [0,1]. Further, the entire
similarity matrix ⇥ follows the distribution
p(⇥|⌧ ) =
Y
k<m
p(✓km|⌧km) (4.10)
4.2.4 Marginal Variable Selection Prior
The equation (1) shows that for a given k, the prior probability of the inclusion of
predictor j given that the predictor is not selected by any rest of the regressions, or
✓km = 0 for all m 6= k is
p( kj|⌫j) = e
⌫j
1 + e⌫j
(4.11)
where ⌫j serves as the parameter that adjusts the sparsity of all the regressions and
also allows the flexibility in selection of particular predictors. Smaller ⌫j leads to lower
marginal inclusion probability of the jth predictor for all regressions, so as to impose
the overall sparsity, which in application, will give us more interpretable results. We
denote the above marginal probability as qj and to induce the flexibility, we set up
a prior for qj in our analysis. Since the prior needs to be flexible enough to cover
the probability range (0,1), we chose Beta prior distribution Beta(a, b). As can be
indicated, parameter ⌫j = logit(qj), the prior for qj also serves the prior for ⌫j with
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the transformed prior distribution as
p(⌫j) =
1
Beta(a, b)
ea⌫j
(1 + e⌫j)a+b
(4.12)
where a and b are fixed hyperparameters that adjust the prior value of qj. To incor-
porate the prior belief of the sparsity of the overall regressions, a prior which leads
to lower qj is favored, such as Beta(1, 7). In application, the specific values can be
adjusted taking account the sparsity of the specific case. If it is believed that most of
the predictors are not selected by any of the regressions and the ones that are selected
are more likely to be the shared ones, people may consider set up a prior that favors
small value of qj with the prior that leads to larger ✓km values.
4.3 Posterior Sampling and Model Selection
Considering we have K regressions, for each regression, we have P predictors. Given
the above prior settings and the likelihood, the full distribution can be written as
KY
k=1
n
p(Yk| k,  2k)p( k| k,  2k)
PY
j=1
[p( kj|⌫j,⇥)p(⌫j|a, b)]
o
p(⇥|⌧ )p(⌧ ) (4.13)
Where the posterior samples of our interested parameters can be acquired by con-
structing a MCMC sampling scheme.
4.3.1 Sampling Scheme
The entire modeling structure shown in equation (1) comprises K regressions, in
our sampling scheme, we run the regression univariately, but taking account of the
shared information incorporating similarity matrix ⇥ into the prior setting of  .
As can be indicated, the top level of the MCMC scheme involves spike-and-slab for
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each of the regression. Specifically, for the kth regression, sampling  k and  k based
on proper prior information. Here, for the normal ’slab’ portion, in our analysis, we
applied independent prior setting as shown in equation (2), assuming each regressor
e↵ect follows the same distribution and is independent. Other widely used conjugate
priors (g-prior and fractional prior) can also be used under some specific cases.
To get more e cient and fast sampling of the coe cients of each regression, we
adapt SSVS approach of George and McCulloch (1993) (cite). We then sample
the similarity matrix ⇥ and the indicator matrix ⌧ from the conditional posterior
distribution applying Metropolis-Hastings method incorporating between-model and
within-model moves, in another word, reversible jump MCMC sampling approach.
Last step involves the sampling of ⌫ with traditional Metropolis-Hastings steps.
In summary, our MCMC sampling scheme can be described as follows with the
detailed sampling procedure described in Appendix B.1. For each iteration t,
• Update  k,  k and  2k for each regression, k = 1, 2, ..., K.
• Update each element ✓km and ⌧km for similarity matrix ⇥ and indicator simi-
larity matrix ⌧ , 1  k < m  K.
• Update predictor-specific marginal inclusion probability parameter ⌫j where
j = 1, 2, 3, ..., P and P is total number of the predictors for each regression.
4.3.2 Model Selection
Our approach to carry out the signal selection is via the estimation of the posterior
probability of the  kj = 1, indicating the inclusion of the jth variable for the kth stra-
tum, with the proportion directly calculated from MCMC interaction after burn-in
samples. We then propose variable selection procedure by setting up a threshold  
and regard the corresponding covariate xkj to be significant if the posterior proba-
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bility of  kj = 1 larger than  . In our model selection, we choose   equal to 0.5 based
on the median rule set by Barbieri and Berger [9]. To infer the magnitudes, we refer
to MCMC summary of  kj, which is calculated from the marginal posterior mean, at
each iteration, conditioning on the inclusion of the corresponding covariate ( kj = 1).
Similarly, to detect the similarity in variable selection between the mth and the kth
strata, we refer to the summary of indicator parameter ⌧km from MCMC samples,
we conclude that there exists significant similarity if the correponding posterior
probability larger than 0.5. The magnitude of the similarity can also be calculated
based on the conditional posterior mean from MCMC iterations.
Another parameter that we are interested in is ⌫j which, with its inverse logit,
indicates the marginal inclusion of the jth covariate across all the strata. The
summary of this parameter vector demonstrates the baseline covariate inclusion
probability across strata without borrowing strength of the similarity.
4.4 Simulation
In our simulation, we apply our methodology framework with di↵erent scenarios that
vary in true sparsity and the standardized coe cients or beta coe cients (absolute
coe cient standard deviation). We check the performance of our model in terms of
the parameter convergence and the estimation accuracy. Then, we compare the our
approach with other alternative models, and illustrate how our model outperforms
others in detecting the signals with higher accuracy and in learning the similarity
structure among multiple strata groups.
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4.4.1 Performance Checking and Parameter Estimation
In this simulation, we consider 5 di↵erent strata (K = 5) and 50 total predic-
tors (P = 50), forming 5 groups, each expressed with one regression formulation
with di↵erent sample sizes. Specifically, we draw random design matrix Xk
from the distribution N (0, Ik), for k = 1, 2, 3, 4, 5 respectively with sample size
n1 = 20, n2 = 50, n3 = 70, n4 = 100, n5 = 150. Also, we consider two degrees
of the sparsity, one with 5 true signals for all strata (sparsity 5/50), one with 10
true signals (sparsity 10/50). Moreover, for each sparsity level, we incorporate
4 di↵erent standardized coe cient levels 0.4, 0.5, 0.7 and 1, where they merely
di↵er in magnitudes with common residual standard deviation equal to 0.3 which
is approximately the calculated standard deviation of our real data. Thus, the
true coe cients are sampled from normal distribution respectively centered around
0.4⇥ 0.3, 0.5⇥ 0.3,0.7⇥ 0.3,1⇥ 0.3 with low standard deviation (0.01) which ensures
small variation in the magnitudes. The response vector for each stratum is sampled
from the distribution N (Xk k, 0.3Ik). Intuitively, larger sparsity leads to fewer
shared signals, and higher standardized coe cient level indicates stronger signal,
yields to higher accuracy in the signal detection.
Here in our context, we only illustrate the performance of the first scenario,
which has sparsity 5/50 with standardized coe cient 0.5. The performance of other
scenarios will be shown in Supplementary materials.
We construct the true signal structure that all 5 strata have the same number
of the signals as shown in the left panel of Figure 4.2, however, they di↵er in
overlapping signals, in another word, they have di↵erent pairwise similarity in signal
structures. The calculated proportion of the signals shared between strata can be
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regarded as empirical estimate of ⇥, which is:
shared signal proportion =
266666664
1 0.67 0 0.43
0.67 0 0.43
0.11 0.43
0
377777775
For prior settings in the simulation, we assign ↵✓ = 2 and  ✓ = 4 for Gamma(↵✓,  ✓)
as the prior distribution for the slab part of the mixture prior defined in Equation
(8), the hyperparameters in this Gamma distribution could be adjusted conditioning
on ↵✓ > 1 which results in a nonlocal prior mentioned in Section 4.2.4. Simultane-
ously, hyperparameters that result in large ✓km also needs to be avoided, so as to
prevent the exhibition of phase transition described in details in Li and Zhang et al.,
2010 [65]. Therefore, we consider 0.5 as the mean in the similarity magnitude given
the inclusion of the pairwise similarity, that favors strong prior belief that the strata
share more signals, together with small qj prior probability (a = 1, b = 9 in Equation
(12)) that forces sparsity in that 10% of the predictors can be selected as signals
as the baseline across all the strata for all predictors, is reasonable in our setting.
However, higher qj prior probability and lower similarity prior probability can be
applied if one believes in more baseline signals, but fewer shared ones across the strata.
In the modeling implementation, we ran MCMC sampler with 30000 iterations,
the result summary comes from 15000 iterations as burn-in samples and 15000 for
inference. To check the convergence, Figure 4.3 shows the traceplots of the number
of the detected signals for each strata regression, which illustrates the convergence.
The figure shows proper mixing without strong trend in the estimation of the number
of signals. Moreover, the posterior probability of inclusion (PPI)of jth predictor for
the kth stratum can be calculated by PPI( kj = 1) =
1
T S
PT
S+1 I( kj = 1) where
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T = 30000, S = 15000. Right panel of the heatmap in Figure 4.2 shows the signal
PPI of all 5 strata for the same scenario in our simulation. The estimated pattern
indicates that our PPI estimation approximately matches with the true signal. To
further assess the detection accuracy, we applied receiver operating characteristic
(ROC) curve that can demonstrate the performance of variable selection when
discrimination threshold is varied, with the Area Under the Curve (AUC) calculated,
as illustrated in Figure 4.4 for each stratum. The AUC was 1.00 for stratum 5, which
indicates perfect AUC can be reached when sample size is large enough in which
case the variable selection is weakly a↵ected by the prior setting, which, satisfies our
desire to have strata which are not influenced too much by borrowing strength given
enough sample size to support the detection power, thus can be e↵ective in leading
e↵ective and better signal selection for other strata with small sample sizes borrowed
strength from these “strong” strata. The AUC was 0.9867 for stratum 4, 0.9956 for
stratum 3 and 0.9733 for stratum 2, which illustrate high accuracy performance.
Stratum 2 achieved 0.9689 AUC value, which is lower given its limited sample size,
but still high enough to obtain the correct signal detection.
To test the detection stability and reproducibility, we implemented our model
for 50 replicates, with the averaged TPR, FPR and AUC calculated for each stratum
with the standard deviation with displayed in parentheses in Table 4.1. The table
clearly illustrates high AUC and low FPR in general, and with great stability
due to small standard deviation. We noticed that for the first stratum having
smallest sample size, the standard deviation of the performance assessment is com-
paratively larger, which is reasonable and within the normal range given the situation.
Besides the signal detection for each stratum, we check the marginal PPIs for
similarity matrix ⇥ with each o↵ diagnal elemented estimated as PPI(✓km = 1) =
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1
T S
PT
S+1 I(⌧km = 1) where T = 30000, S = 15000 and 1  k < m  K and I
represents the indicator function. We noticed that the matrix estimation approx-
imately match with the real shared linkage proportion in a way that higher value
represents larger commonality pairwisely. The posterior mean indicates the extent
of the similarity, which also provides our general information of how similar in terms
of the signal selection between and among all the strata. We also calculated the
standard deviation of the similarity matrix based on 50 replicates, the low deviation
demonstrates high stability.
Thus, our methodology framework can obtain proper convergence and strong
reproducibility with performance results in high signal detection accuracy and
comparatively informative similarity estimation.
TPR FPR AUC
k=1 0.476 (0.193) 0.0067 (0.012) 0.9632 (0.035)
k=2 0.86 (0.158) 0.0182 (0.024) 0.9841 (0.025)
k=3 0.968 (0.084) 0.0138 (0.018) 0.9982 (0.004)
k=4 0.952 (0.086) 0.0156 (0.015) 0.9972 (0.006)
k=5 0.992 (0.04) 0.0102 (0.016) 0.9997 (0.001)
Table 4.1: Simulation Results on 50 constructed data sets. Averaged true positive rate
(TPR), false positive rate (FPR) and area under curve (AUC) with the corresponding
standard deviation across the data sets.
sd(PPI(⇥)) =
266666664
0.03 0.0.3 0.02 0.03
0.05 0.04 0.04
0.05 0.04
0.04
377777775
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Figure 4.2: Modeling Result: left panel shows the true signal in our simulation setting
with 50 predictors and 5 strata; right panel shows the posterior probability of inclusion
(PPI) of our model, darker color indicated high posterior probability.
4.4.2 Performance Comparison
Further in the simulation, we implemented alternative approaches and compare their
performances with ours. Specifically, we consider 4 other methods covering two types
of possible solutions, one is separate regression estimation, the other one is pooled
data with single regression. Two variable selection methods are considered for both
of the solutions, spike and slab [75] and LASSO [107], which are typical methods
respectively belong to Bayesian and Frequentist framework.
We generate 50 random normal datasets with the same similarity matrix ⇥
90
Figure 4.3: Traceplot: the traceplot of the number of the signals selected across MCMC
samples with burn-in samples removed. It shows great convergence, which indicates proper
mixing and the feasibility of our Linked-regression model.
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Figure 4.4: ROC curve: checking the ROC curve and the AUC of our model for the first
senario, the computed AUC shows high accuracy of the signal detection for all 5 strata
regression.
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and implement the MCMC sampler and get the parameter summary based on
MCMC samples for each replicate. The final results for the model comparison are
summarized based on the analysis of 50 replicates . For each dataset, we apply our
linked regression approach, marginal spike and slab method, marginal lasso method,
pooled spike and slab method and pooled lasso method, we briefly name these
methods in respectively in Table 4.2 as “BLINK”, “mar ss”, “mar lasso”, “pool ss”
and “pool lasso”. For spike and slab, we set 0.5 as the prior variable inclusion
probability and the result is estimated based on posterior probability. For lasso
method, considering its randomness of the selection [107] we implement stability
selection [73] so as to obtain the probability of the inclusion of the features. For all
these methods, we implement with 30000 iterations and we regard the features to
be significant if the posterior probability or the selection stability probability larger
than 0.5.
Results on signal detection of di↵erent methods are shown in Table 4.1, which
is based on standardized coe cient 0.5 at sparsity 5/50. The comparison of the
performances for other scenarios is demonstrated in Supplementary materials. Fig-
ure 4.5 provides us visualized results that compare the AUC and TPR of di↵erent
methods with the same FPR 0.05. It demonstrates that the averaged AUC and TPR
of our model overperform the those of other alternative models for the first three
strata when the sample size is relatively small. For last two strata with larger sample
sizes, our linked-regression model tends to be slightly lower, but similar in general.
The result meets our expectation that our model benefits more for the strata having
smaller sample size with weaker strength in signal detection, for large sample strata,
our model tends to make little influence on the posterial inference, so as to guarantee
e↵ective borrowing strength, in another word, we eager to borrow the information
from the right signals detected for strong strata to weak strata.
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To further check the comparison of the stability of the estimating results, Ta-
ble 4.2 provides the averaged AUC, FPR and TPR with the corresponding standard
deviation for all 5 models with fixed FPR controlled at 0.05. It shows that for strata
with smaller sample size (eg. k = 1,k = 2 and k = 3), the TPR as well as the AUC
calculated from our method uniformly outperforms that of others, leaving similar
performance or slightly weaker performance for strata with large sample size. Our
model is demonstrated to be stable and reproducible given that it has comparatively
small standard deviation across 50 replicates than that of the other methods.
Figure 4.5: AUC and TPR Checking for model comparison with fixed FPR controlled at
0.05
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K=1 (n=20) K=2 (n=50) K=3 (n=70)
Model TPR (SE) FPR (SE) AUC (SE) TPR (SE) FPR (SE) AUC (SE) TPR (SE) FPR (SE) AUC (SE)
BLINK 0.832 (0.142) 0.05 (0) 0.9632 (0.035) 0.92 (0.128) 0.05 (0) 0.9841 (0.025) 0.996 (0.028) 0.05 (0) 0.9982 (0.004)
mar ss 0.336 (0.254) 0.05 (0) 0.7469 (0.124) 0.736 (0.254) 0.05 (0) 0.9365 (0.07) 0.944 (0.107) 0.05 (0) 0.9836 (0.029)
mar lasso 0.308 (0.233) 0.05 (0) 0.7244 (0.134) 0.716 (0.249) 0.05 (0) 0.9303 (0.075) 0.896 (0.141) 0.05 (0) 0.9716 (0.046)
pool ss 0.688 (0.141) 0.05 (0) 0.8864 (0.069) 0.688 (0.141) 0.05 (0) 0.8864 (0.069) 0.808 (0.156) 0.05 (0) 0.9637 (0.038)
pool lasso 0.684 (0.14) 0.05 (0) 0.89 (0.069) 0.684 (0.14) 0.05 (0) 0.89 (0.069) 0.804 (0.164) 0.05 (0) 0.9628 (0.046)
K=4 (n=100) K=5 (n=150)
Model TPR (SE) FPR (SE) AUC (SE) TPR (SE) FPR (SE) AUC (SE)
BLINK 0.98 (0.061) 0.05 (0) 0.9972 (0.006) 1 (0) 0.05 (0) 0.9997 (0.001)
mar ss 0.992 (0.04) 0.05 (0) 0.9982 (0.005) 1 (0) 0.05 (0) 1 (0)
mar lasso 0.988 (0.048) 0.05 (0) 0.9974 (0.007) 1 (0) 0.05 (0) 0.9997 (0.001)
pool ss 0.024 (0.077) 0.05 (0) 0.7813 (0.088) 0.848 (0.164) 0.05 (0) 0.9647 (0.047)
pool lasso 0.044 (0.093) 0.05 (0) 0.7698 (0.089) 0.848 (0.169) 0.05 (0) 0.9648 (0.047)
Table 4.2: Model Comparison Result: True Positive Rate (TPR) and Area Under the Curve (AUC) are shown in this table for all the
methods, with the mean calulcated across 50 replicates with False Positive Rate (FPR) being controlled at 0.05. The numbers inside
parentheses are the corresponding standard deviation.
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4.4.3 Computational Information
As with the computational time, for a single replicate, our linked regression model
takes approximately 30 hours with 30000 iterations, using computing server with
96GB memory space and 12 total cores. To implement the multiple replicates, we
applied parallel computing using in-house clusters, which took same amount of time.
Considering high dimensionality in data sets, complicated prior settings and Bayesian
sampling scheme, the computing time is reasonable. Computational time reduction
could be implemented by incorporating parallel computing strategy inside the sam-
pling process or applying more advanced programming languages and etc., which will
be further investigated in the future.
4.5 Application
We apply our methodology to RPPA based pathway analysis incorporating the
genomic and epigenomic upstream factors across multiple cancer types belonging
to the same pan-cancer group assuming that they have shared RPPA regulatory
mechanisms. Our goal is to apply our methodology framework in detecting the
key upstream factors that a↵ect RPPA based pathway activities for multiple cancer
types, borrowing strength and learning the similarity mechanisms via analyzing the
common factors that are detected by di↵erent cancer types.
Our integrative analysis comprises multiple genomic platform profiles as upstream
factors including mRNA, microRNA, copy number alteration and methylation. As
the outcomes, we focus on pathway activities at protein level, and more specifically,
we explored 12 biologically important pathways from the aspect of tumor cell be-
havior and therapeutic response. As described in TCGA RPPA study by Akbani
et.al [4], these pathways are: apoptosis, breast reactive, cell cycle, core reactive,
96
DNA damage response, EMT, PI3K/AKT, RAS/MAPK, RTK, TSC/mTOR, hor-
mone receptor, and hormone signaling (breast). Pathway-Gene membership table
is shown in Supplementary materials. Di↵erent cancer types can be investigated
using our methodology framework, in our application, we focus on multiple cancer
groups based on di↵erent resources of recent studies. For example, recent study
analyzed gynecological and breast cancer types aiming to identify commonality
and di↵erence in their features at molecular level through comprehensive analysis
of molecular data containing 2579 tumors from TCGA [11]. The study typically
focuses on five cancer types: Breast invasive carcinoma (BRCA), Cervical squa-
mous cell carcinoma and endocervical adenocarcinoma (CESC), Ovarian serous
cystadenocarcinoma(OV), Uterine Corpus Endometrial Carcinoma (UCEC), Uterine
Carcinosarcoma (UCS), which are taken together as “Pan-Gyn” cohort, which
we regard it as one of the target cancer groups to be applied with our modeling
approach. Similarly, the analysis overview for Pan-Kidney cohort containing Kidney
Chromophobe (KICH), Kidney Renal Clear Cell Carcinoma (KIRC) and Cervical
Kidney renal papillary cell carcinoma (KIRP), has been published online as in
Broad Institute TCGA Genome Data Analysis Center (2016) in public website
“http://gdac.broadinstitute.org/runs/analyses 2016 01 28/reports/cancer/KIPAN-
TP/index.html”. Although each cancer organ site contains specific biological process,
we target to study the commonality and distinctions of the RPPA based pathway
drivers for each pathway and throughout all three cancer types. Moreover, another
pan-cancer group that we focus on is Gastro-Intestinal (GI) cancer group, which
defines the group of cancers that influence digestive system. This group includes
Stomach adenocarcinoma (STAD), Esophageal carcinoma (ESCA), Colon adeno-
carcinoma (COAD), Rectum adenocarcinoma (READ). Also, as study shows most
recently that integrative analyses of genetic and epigenetic alterations has been
implemented for PanCancer Atlas study showing the identifiability in distinguishing
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molecular factors of squamous cell carcinomas (SCCs) from other cancer types. The
Pan-Squamous includes Head and Neck squamous cell carcinoma (HNSC), Lung
squamous cell carcinoma (LUSC), esophageal (ESCA), cervical (CESC), and bladder
cancers (BLCA) [81] [82] [83] [83]. Thus, for each cancer group, we explore the
key drivers for di↵erent pathways, assuming that the cancer types within the same
pan-cancer group can have shared common genomic and epigenomic factors that
a↵ect the specific RPPA based pathway phenotype.
4.5.1 Data Description
4.5.1.1 RPPA based pathway activity score
To measure the RPPA based pathway activities, tissue specific pathway scores need
to be calculated and incorporate into the integrative model as outcomes. Instead
of using gene expression data sets, the pathway score is calculated based on RPPA
data sets. Considering that the pathway score needs to be unsupervised and yields to
single sample in our case. Di↵erent methods lie in this category, such as combined z-
score, single sample Gene Set Enrichment Analysis (GSEA), Pathway Level analysis of
Gene Expression (PLAGE) [8] [62] [109] and gene set variation analysis (GSVA) [35].
We can apply di↵erent methods in our study, here, in our framework, we chose to
utilize combined z-score based on RPPA data, which is derived based on proteomic
expression of the proteins belonging to specific pathway. Thus, for a specific pathway,
for the kth cancer, we calculate the RPPA based pathway score as the outcomes
denoted as yk with dimension nk⇥1 where nk is the number of the samples that have
RPPA information.
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4.5.1.2 Genomic Upstream Factors
We consider genomic and epigenomic drivers as large molecular covariates that af-
fect the RPPA based pathway activities. The multiplatform genomic data involves
mRNA, microRNA, copy number alteration (CNA) and methylation. Consider a spe-
cific pathway, we eager to investigate K cancer types, with index k ranging from 1 to
K. For the kth cancer, following shows how we retrieve multiplatform genomic data
and form it as design matrices for this specific pathway.
• mRNA
Based on pathway-gene membership table in Appendix B.2, we include the gene
expression of the genes that belong to this pathway, we retrieved and applied
standardized gene level tumour tissue RNAseq data collected by Illumina and
HiSeq that can be downloaded and retrieved through utilizing a recent developed
R package “GeneSurvey” that can be accessed online “https://github.com/MD-
Anderson-Bioinformatics/GeneSurvey”. The mRNA data set can be repre-
sented as XmRNAk with dimension n
mRNA
k ⇥Pk where nmRNAk denotes the mRNA
sample size for the kth cancer and Pk is the number of the genes in this pathway.
• microRNA
Our microRNA data was retrieved using package “GeneSurvey” as well. To
e↵ectively acquire the microRNA values that should be included into the
model, we referred to multiMiR R package and database which investigated
the microRNA-mRNA interactive associations across disease and drug associa-
tions [93]. For each gene, we collected and include the related microRNA as our
covariate if the interaction is validated in multiMiR study. The microRNA data
matrix can be represented as XmicroRNAk with dimension n
microRNA
k ⇥PmicroRNAk
where nmicroRNAk denotes the microRNA sample size for the k
th cancer and
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PmicroRNAk is the number of microRNAs that interact with the genes in the
pathway.
• CNA
For copy number alteration, we retrieved and obtained the gene level standard-
ized summary of CNA (SNP 6 ( HG19,no CNV and no sex chromosomes ))
for each gene within the pathway, using “GeneSurvey”. Normal samples were
filtered out, leaving tumour tissue samples, forming our CNA data matrix de-
noted as XCNAk with dimension n
CNA
k ⇥Pk where nCNAk denotes the CNA sample
size for the kth cancer and Pk is the number of the genes in this pathway.
• Methylation
The Methylation data we collected using package “GeneSurvey” was Human
Methylation 450 data sets. It was processed from level 2 to level 3. Thus,
it is also gene level summarizing dataset. For each gene in the pathway, we
retrieved the corresponding CpGs , more specifically, we collected the CpGs
of the methylation sites that are located at specific position of the gene body
with specific distance from its transcription start site (TSS), eg. annotated
as TSS1500 or TSS200. Here in our analysis, we include them all matching
with each of the genes. The data matrix can be represented as XMethyk with
dimension nMethyk ⇥ PMethyk where nMethyk denotes the methylation sample size
and PMethyk is the total number of the methylation CpG values.
Thus, in this way, multiplatform data collection is processed. However, given the
fact of the heterogeneity in the sample sizes of di↵erent genomic profiles and our
model requires the consistency of the sample size, we further checked the intersection
of the sample sizes and established a new set of datasets with the reduced matched
samples. Table B.2 in Appendix B provides the summary of the sample size of
di↵erent platform for all the TCGA cancer types.
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We define the response vector as well as the covariate matrix as yk and Xk =
{XmRNAk , XmicroRNAk , XCNAk , XMethyk } for the kth stratum, and we implemented our
metholodogy using the data sets which have already been processed. The final
modeling results were computed based on 30000 MCMC sampling iterations, with
15000 as burn-in samples and another 15000 as the basis for final inference. Signals
were detected based on posterior inference, as described in our Simulation Section,
we regard the covariates as significant if marginal PPI > 0.5.
4.5.2 Modeling Results and Biological Interpretation
The modeling results in our case study contain two main parts. First, we target to
find the genomic and epigenomic upstream factors that a↵ect specific RPPA based
pathway activities. Second, we focus on measuring how “similar” the RPPA based
pathway is for each group of cancer types by investigating the similarity matrix,
higher similarity means more common factors shared by these cancer types for a
specific pathway. We examine the results group by group and illustrate the results
through figures and descriptions with biological interpretation.
To biologically interpret the results, we focus on Pan-Gyn group upstream factor
selection and the similarity inference, and we also check the common similar pathways
and upstream factors across all cancer groups. The application results for other pan-
cancer groups their interpretations could be further investigated biologically similarly.
Regarding with the cancer group specific results, the upstream factor selection
for each cancer type is illustrated in Figure 4.6, Figure 4.9, Figure 4.11, and Fig-
ure 4.13. The e↵ective similarity among di↵erent cancer types within each group is
shown in Figure 4.8, Figure 4.10, Figure 4.12 and Figure 4.14. Overall, we noticed
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that among all 4 groups, pathway Hormone signaling (Breast) is the one that has
the e↵ective similarity in its driving factors across all groups. When checking the
results into details, we found that BCL2, which is a gene belonging to this pathway,
with its mRNA as the key factor that a↵ect the protein pathway activity across
all the cancer types within Pan-Gyn group. GATA3 and INPP4B are another
two genes with their gene expression selected to be significant in driving Hormone
signaling pathway activity across 3 cancer types BRCA, CESC, and UCEC. The
result is in agreement with the literature that GATA3, as a transcriptional activator,
is frequently highly expressed by luminal epithelial molecular cells in the breast.
Study found that GATA3 is among of the top genes that have low expression in
carcinomas and lead to poor clinical outcomes [72]. Also, study showed that GATA3
is a sensitive and specific marker in diagnosing breast and urothelial carcinomas [68],
thus, with its importance, it can a↵ect the aforementioned cancer types via influenc-
ing their important signaling pathway activities. INPP4B, as discussed in previous
studies, was discovered to be tumor suppressor [25] [31] [115], with evidence from
various studies in breast, prostate, and ovarian cancers [89] [96] [42]. Particularly,
INPP4B was found to suppress epithelial cell transformation in human breast cancer
studies [42]. The common Hormone signaling (Breast) pathway with the significant
e↵ective similarity among all cancers indicate that similar patterns of the associations
between upstream factors mapped with the proteins/genes with Hormone signaling
(Breast) pathway can be drawn across all cancer groups, which can further infer that
the hidden associations remain similar across all cancer types. The inference could
be potentially given further validation and the results will lead to therapeutic target
finding across all cancer types that belong to the four groups.
For a specific cancer type, various functional proteomic regulators were selected
as clearly illustrated in Figure 4.6 for Pan-Gyn group. For all 12 pathways, di↵erent
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numbers of regulators are selected for di↵erent individual cancer types. In general,
there are more microRNAs that are selected due to multiple microRNAs mapping
with the same gene. CNA is not frequently selected throughout the pathways,
and important CpGs are selected as important, which a↵ect gene expression and
indirectly influence proteomics and the signaling pathway activities.
Figure 4.8 illustrates the e↵ective similarity linkage of the upstream factors that
a↵ect 12 RPPA pathways. The linkage shown in this figure all have similarity PPI
above 0.5, and the width of the linkage corresponds with the similarity strength.
Thus, it can be inferred that, for Gyn group containing 4 cancer types, 7 pathways
share similar key drivers between at least one pair of the cancers. More specifically,
Apoptosis pathway owns e↵ective similarity in shared drivers across all the cancers,
indicating that all 4 cancer types have shared drivers that a↵ect this pathway.
Further, Figure 4.7 shows that these cancer types share one common gene “BCL2”,
which reflects biological aspect that BCL2 was the first gene that inhibits apoptosis
signaling pathway in any species, and its critical role has been further investigated
recently as cancer target in Adams et al., 2018 [1]. We also noticed that receptor
tyrosine kinase (RTK) pathway has more e↵ective similarity linkages especially
between BRCA and UCEC, with higher magnitude. When checking the cancer and
pathway specific upstream factors, it shows that gene expression of EGFR serves
as the common factors among BRCA, CESC and UCS cancer types. EGFR serves
as a key regulator of RTK signaling pathway and is found to be overexpressed in
breast cancer tissues, that leads to accelerated tumor growth [63] [17]. Moreover,
the copy number of gene ERBB2 is the common drivers for cancer types BRCA,
CESC and UCEC for RTK pathway as well, biologically given that ERBB/HER
belongs to one of the subfamilies of RTK, which includes gene ERBB2, with its
amplification in the gene copy number, is discovered in leading to overexpression
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of cell proliferation in various of cancer types [22] [46] [16]. Specifically, Hormone
receptor signaling pathway has large similarity magnitude among all linkages between
UCEC and BRCA, indicating larger commonality in their selected regulators. As
can be illustrated from the Figure 4.6 and Figure 4.7, they have same two genes
ESR1 and PGR, with the expression pointed out to be significant. Study showed
that ESR1 amplification is a common mechanism in proliferating breast cancer [44]
and in endometrial carcinoma [61]. Most recent research showed that PGR is one
of the important transcriptional regulatory key factors associated with breast cancer
molecular subtypes for Estrogen Receptor (ER), which serves as an important
therapeutic target in breast cancers [92]. Thus, common targets between UCEC and
BRCA serve as potential therapeutic targets in activating or deactivating Hormone
receptor signaling pathway and its related functional proteomic activities.
4.6 Discussion
In this work, we have established a novel linked regression modeling strategy that
addresses the multi-stratum regression problem. This Bayesian hierarchical modeling
framework allows flexibility in borrowing strength among multiple strata while doing
signal detection for each stratum. This approach has been shown having several
key advantages: (1) higher signal detection accuracy compared with other relevant
approaches with the benefit of borrowing strength, especially for rare disease having
small sample size; (2) capability of estimating the similarity of the common factors
that are selected for di↵erent strata; (3) signal detection and similarity estimation
are processed simultaneously so that it adaptively borrows strength across strata
dynamically. We noticed that our method benefits more to stratum with small
sample size, which rely more on prior settings, for large sample stratum, the benefit
is limited while still within proper range.
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Figure 4.6: Upstream factor detection of Pan-Gyn group: genetic and epigenetic factors
that are selection for each cancer and for each pathway using our method are highlighted
in di↵erent colors as illustrated in the legend.
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Figure 4.7: Table of Upstream factor detection of Pan-Gyn group
We applied our methodology into pan-cancer group analysis, regarding stratum
as di↵erent cancer types, dependent variable as RPPA based pathway activity
scores, and regressors as genetic or epigenetic upstream factors. This particular
case study targets to investigate key molecular drivers that influence protein level
pathways for each cancer type within a specific group while borrowing strength of
the detection across cancer types by assuming that the cancer types in the same
pan-cancer category have similarity in their driving upstream factors for a specific
pathway. We analyzed 4 pan-cancer groups and 12 important signaling pathways.
We identified significant upstream factors for each cancer type and at the same
time, we inferred the similarity in common factors for each group for any of the
12 pathways. Thus, our method provides a strategy that investigates common
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Effective Similarity Linkage for Pan-Gyno
BRCA
CESC
UCEC
UCS
Apoptosis
Cell cycle
DNA damage response
EMT
Hormone receptor
Hormone signaling (Breast)
RTK
Figure 4.8: The e↵ective similarity linkage for Pan-Gyn throughout the pathways, the
pathways listed and illustrated with di↵erent colors indicate that 7 pathways select similar
upstream regulators. Larger linkage width represents higher similarity.
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Figure 4.9: Upstream factor detection of Pan-Kidney group: genetic and epigenetic factors
that are selection for each cancer and for each pathway using our method are highlighted
in di↵erent colors as illustrated in the legend.
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Effective Similarity Linkage for Pan-Kidney
KICH
KIRC
KIRP
Apoptosis
Core reactive
DNA damage response
Hormone signaling (Breast)
RTK
Figure 4.10: The e↵ective similarity linkage for Pan-Kidney throughout the pathways, the
pathways listed and illustrated with di↵erent colors indicate that 5 pathways select similar
upstream regulators. Larger linkage width represents higher similarity.
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Figure 4.11: Upstream factor detection of Pan-Squamous group: genetic and epigenetic
factors that are selection for each cancer and for each pathway using our method are high-
lighted in di↵erent colors as illustrated in the legend.
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Effective Similarity Linkage for Pan-Squamous
ESCA
HNSC
LUSC
Apoptosis
Cell cycle
Core reactive
DNA damage response
EMT
Hormone signaling (Breast)
Figure 4.12: The e↵ective similarity linkage for Pan-Squamous throughout the pathways,
the pathways listed and illustrated with di↵erent colors indicate that 6 pathways select
similar upstream regulators. Larger linkage width represents higher similarity.
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Figure 4.13: Upstream factor detection of Pan-GI group: genetic and epigenetic factors
that are selection for each cancer and for each pathway using our method are highlighted
in di↵erent colors as illustrated in the legend.
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Effective Similarity Linkage for Pan-GI
COAD
ESCA
READ
STAD
Hormone signaling (Breast)
Figure 4.14: The e↵ective similarity linkage for Pan-Gyn throughout the pathways, the
pathways listed and illustrated with di↵erent colors indicate that only 1 pathways select
similar upstream regulators. Larger linkage width represents higher similarity.
molecular drivers that influence some specific pathway activity across cancer types,
eg. mRNA BCL2 is the common driver of gynecologic cancer group for Apoptosis
pathway, which will potentially serve as an important therapeutic target in clin-
ical field. Similarly, other molecular profiles including CNA, methylation as well
as microRNA can also be regarded as pathway specific switches based on our analysis.
In summary, our methodology framework provides a way to link multiple re-
gressions adapted to multiple strata with the same set of covariates, based on the
assumption that similarity lies in that some strata share common true significant
covariates. Although in our case study, we treat the strata as cancer types, the strata
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that we described can take any forms in real practice, such as patients coming from
di↵erent region, races and age levels. We believe that our methodology benefits the
signal detection for each stratum, and similarity inference among multiple strata by
capturing if the strata share common factors and to what extent.
However, this project has some weaknesses. First, Given the complexity of the
model which simultaneously performs variable selection for each stratum and learns
the similarity matrix, the model is not likely to work well in settings for which
all strata have very small sample sizes. Another limitation lies in that we do not
incorporate interaction term such as considering the association between neighboring
genes or CpG sites, or involving modeling nonlinear relationships between pathway
activity and genomic upstream factors.
In our framework, possible extensions and generalizations could be implemented
in our future work. One extensive direction may be incorporating nonlinearity
into our modeling strategy allowing more flexibility in the relationship between
dependent variable and covariates. Another direction may be imbedding into group
selection for each stratum specific regression allowing horizontal borrowing strength
simultaneously. These directions will therefore be of interest in future work.
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Chapter 5
Conclusion
In this dissertation, we have introduced novel methods for integrative analysis of
omics data with topics ranging from radiogenomics analysis, pathway driver inte-
grative analysis and proteomic based pathway pan-cancer analysis. To start the
navigation of the integrative analysis, we started our exploration of radiogenomics
which digs into the hidden associations between imaging and genetics incorporating
genomic biological mechanisms of multiple platforms using Bayesian hierarchical
methodology framework. In Chapter 2, we established a multi-stage framework
comprising genomic model which incorporates multiplatform genomic associations,
radiogenomic model which investigates the relationships between radiomic features
and genomic features. In the process, we dealt with high dimensionality in radiomic
features applying Sparse PCA algorithms, which we established Radiomic-meta-
Features that can be viewed as radiomic representatives of the original imaging
features. In order to detect significant genomic biomarkers associated with RmF and
the important RmFs that are related with clinical outcomes, we applied Bayesian
adaptive shrinkage method to do features selection, more specifically, we utilized
normal gamma prior for the analysis and simultaneously we allowed platform specific
e↵ect on each RmF by incorporating platform specific hyperparameters. We applied
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Radio-iBAG to a glioblastoma multiforme (GBM) data set from The Cancer Genome
Atlas (TCGA), using survival time as the clinical outcome, and identified several
potential prognostic genes, genomic platforms as well as radiomic features that
implicated in GBM progression.
To explore the integrative analysis of pathway driver detection, we established
pathDrive, a new modeling strategy that involves a penalized regression of pathway
or gene set scores on multi-platform explanatory variables to identify sparse sets of
upstream regulatory factors that can be viewed as key leverage points in the molecular
processes underlying the pathway. The pathway scores integrate information across
genes within a common network, and provide quantitative summaries that are more
functionally relevant than individual gene expressions, and through regression on
potential upstream genetic andepigenetic e↵ectors our strategy has the potentiality
in identifying key factors in the networks that comprise novel genomic upstream
target set. To obtain the sparse molecular upstream target, we applied LASSO with
stability selection as feature selection algorithm. We applied our methodology into
the analysis of colorectal cancer and incorporated its four specific CMS groups into
the selection of the targeted pathways that significantly di↵erentiate CMS subgroups.
We finally detect key factors that drive the activities of those pathways in colorectal
cancer with biological interpretation.
Motivated by pathDrive analysis, we extended the integrative pathway analysis
from single tumor type to multiple tumor types. In Chapter 4, we established a novel
analyzing flow of pathway driver detection when there exists cancer types with small
sample size, we borrow strength of the signal detection from the ones with enough
sample size using Markov Random Field prior setting, which leads to higher power in
signal detection. The construction of the prior setting depends on the hidden similar-
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ity among cancer types in terms of the selection of the upstream drivers for the same
pathway. And simultaneously, the similarity could be measured and estimated from
the model. We applied our methodology into di↵erent cancer groups: Pan-Kidney,
Pan-GI, Pan-Gyn and Pan-Squamous. For each group, we targeted 12 proteomic
based pathways and detected their pathway drivers for each cancer type incorporat-
ing their selection similarity among di↵erent tumor types within that group. Also,
the similarity was estimated for each group and given proper biological interpretation.
The proposed framework also leaves substantial space for future research. Fol-
lowing I list some of the limitations and possible directions for improvement:
1. Radiomics: In Radio-iBAG project, during the imaging preprocessing, we
targeted 2-D pixel based features where they were derived from the imaging slide
which had the largest tumor area. However, more su cient information could be
drawn from 3-D volumetric features where they could be calculated from 3-D tumor
images combining multiple scanning slices. Another direction in Radiomics part lies
in that we can incorporate spatial analysis into radiogenomics framework, directly
associating spatial diversity with genomics and clinical outcomes.
2. Genomics: We include multiplatform genomic factors in all of the analyzing
framework, however, we did not include the relationships and interactions between
neighboring or biological related genes and their corresponding upstream factors.
Future work can extend the analysis by incorporating this information to delineate
a more detailed picture in detecting biological mechanisms, which may involve
advanced computing techniques and more complicated biological interpretations.
3. Pathway: We investigated into the complicated relationships between path-
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way activity and the genetic or epigenetic upstream factors. We focused on detecting
linear relationship, however, it could be further extended into nonlinear relationship
detection that will provide more su cient and complex biological processes. From
another perspective, when choosing the target pathways, in the case study, the
pathways that we aimed were the ones that could significantly di↵erentiate CMS
groups. In the future direction, the target pathways could be extracted based on
other criterion such as the relatedness with clinical outcomes.
This dissertation mainly focuses on integrative analysis of omics data sets cov-
ering multiple areas: radiomics, genomics, proteomics and pathways. It is one of the
first e↵orts in using Bayesian and computational statistical techniques in analyzing
multi-platform data resources aiming to get deeper understanding of biological mech-
anisms and processes. The listed future directions can improve the current study,
which will lead to more accurate biomarkers in the context of precision medicine,
and better analyzing flow for integrative analysis.
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Appendix A
Radio-iBAG Implementation
Details
A.1 Full conditional posterior distribution
The general posterior distribution of the coe cient parameter as well as other
hyperparameters for the regression model either for the Radiogenomic Model or the
Radiogenomic Clinical Model are shown below.
Consider the linear regression formula: Y = X  + ✏.
In the radiogenomic model, Y denotes the specific RF, X is the matrix of the
genomic platform combinations. In the radiogenomic clinical model, Y denotes
the clinical outcome, X represents the RF combinations modulated by di↵erent
gene expression parts explained by di↵erent genomic platforms. The full posterior
distributions are
 |rest ⇠ Normal((XTX +  2D 1⌧ ) 1XTY, (XTX +  2D 1⌧ ) 1 2)
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 2|result ⇠ IG(a+ n/2, b+ (Y  X )T (Y  X )/2)
 ji|rest ⇠ GIG(a =   2j , b =  2ji, p =  j  
1
2
)
 j|rest ⇠ (1/ j)a˜exp{ b˜  2j /(2 j)  c j}⇥
pjY
i=1
 
 j
ji /{( ( j))pj(2 2j )pj j}
  2j |rest ⇠ Gamma(a˜+ pj j, (b˜/ j +
pjX
i=1
 ji)/2),
If applying to the radiogenomic clinical model, j denotes the RF combination that
are modulated by the gene expression that is explained by the jth platform, and
k represents the kth RF; if applying to the radiogenomic model, j is the genomic
platform type index, i is the gene index.
Specifically,  j is sampled through the Metropolis-Hastings method, the pro-
posed family is exp( 2 z) j, and z comes from the standard normal distribution. The
acceptance rate is controlled between 20% and 30%.
A.2 Data Preprocessing for GBM
In this section, we mainly present data preprocessing techniques and procedures,
especially for GBM MRI imaging data, including imaging preprocessing, feature ex-
traction and description. Further, we illustrate our preliminary checking results for
radiomic features (RFs) and describe how radiomic-meta-features (RmFs) are gen-
erated. For the genomic platform data sets, we perform missing value imputation;
detailed information is described in the last subsection.
A.2.1 Radiomic-feature preprocessing
Our GBM MRI imaging data set was downloaded from The Cancer Imaging Archive
with two imaging modalities: T1-post contrast and T2-weighted FLAIR.
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In brief, the dicom MRI images were converted to the nifti format (.nii) using
MRIConvert software (http : //lcni.uoregon.edu/ ⇠ jolinda/MRIConvert/ ). We
then performed pre-processing steps on the MRI images by following a certain
pipeline, and further obtained the 3D tumor volumes. The pipeline is described here.
a. Non-uniformity correction: We used a nonparametric intensity non-uniformity
normalization (N3) correction module in MIPAV (v 6.0) [70] to correct the shading
artifacts that resulted from partial volume averaging errors of the MRI instrument.
The N3 algorithm iteratively estimates the true tissue intensity distribution, as the
shading artifacts lead to reduced signal intensities in certain image regions.
b. Registration: We used medical image processing, analysis and visualization
(MIPAV) software to register the T2-FLAIR N3 corrected images to the respective T1-
POST N3 corrected images. We used the normalized mutual information criterion in
the optimized automatic registration module in MIPAV ((http://mipav.cit.nih.gov/).
c. Segmentation: Semi-automated segmentation of the tumor regions in 3D
was performed by our clinical experts using the Medical Image Interaction Toolkit
3M3 (http://www.mint-medical.de/). This software features slice-by-slice contour
drawing, correction tools and 3D interpolation of the tumor region, which are utilized
to perform the tumor segmentation.
d. Re-slicing: Lastly, we re-sliced the original as well as the pre-processed im-
ages to widths of 1 millimeter using the NIFIT toolbox in MATLAB (http :
//research.baycrest.org/ ⇠ jimmy/NIfTI). Image Feature Computation: Textu-
ral and regional image features. Computer-based texture analysis of medical images
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such as MRI scans depicts some quantitative properties like the measurement of
regional intensity variations. Using these properties in the textural analysis can
further help in the prediction of several factors such as molecular subtypes of the
disease and patient survival times.
In this study, the image-derived textural features are utilized in analyzing the
relationship between imaging data, genomic multiplatform data sets, and clinical
outcomes. For this analysis, we derived textural features from the largest axial
2D slice of the tumor area [122]. These textural features were obtained from the
following two-step process.
1. Image filters: We used Laplacian of Gaussian (LoG) [36] and Gaussian fil-
ters [37] to filter the MR images at five di↵erent scales, so as to obtain fine, medium
and coarse transforms of the 2D tumor region. The LoG filter, commonly used
for edge detection, is a measure of the second spatial derivative of an image. The
Laplacian filter is applied to an image that has been smoothed using a Gaussian
filter; hence, reducing the sensitivity to noise. We used five standard deviations ( )
to derive fine features at 0.2mm and 0.4mm, medium features at 1.5mm and 2.5mm,
and coarse features at 5mm.
2. Texture features and summary measures: In terms of textural features, we
calculated Haralick features for both T2-weighted FLAIR and T1-weighted post
contrast images. The gray-level-co-occurrence matrices (GLCMs) were derived for
both the original and pre-processed images. Further, from the GLCMs, we computed
Haralick statistical features at 4 di↵erent distances (1mm, 2mm, 4mm and 8mm).
Besides the textural features, we obtained some summary features such as the mean
intensity of the images, entropy and uniformity measures. These features are also
122
known as “TxR” features [28]. In addition to the textural features, we computed
the area and mean intensity of the largest tumor slice. These are referred to as the
“regional” features.
After the extraction of the features, we conducted further normalization by cal-
culating two di↵erent ratios: type-1 and type-2. “Ratio type-1” corresponds to the
ratio between the features computed at di↵erent filters and the features computed
from the original images (unfiltered features). “Ratio type-2” corresponds to the ratio
between features computed at the coarsest scale and those computed at the finer scale.
In our analysis, we considered three major types of RFs: Haralick features, his-
togram features and regional features. We have 13 total Haralick features, with
the names and corresponding calculation formulas listed in Table A.1. Histogram
features are calculated from the histogram of the image intensity distribution, with
a total of 3 typical features, including the mean intensity, entropy and uniformity
characteristics, with formula shown in Table A.2. As mentioned in the imaging
preprocessing section, the two regional features that we utilized were the area and
mean intensity of the largest tumor slice.
A.2.2 RF and RmF description
In total, we have 972 RFs that we extracted from the original imaging data. Con-
sidering that some features were extracted from the same imaging modality, or were
processed using the same algorithm, we categorized 972 RFs into 20 groups based on
their properties, extracting procedure and imaging modalities. Table A.3 illustrates
the name of the RF groups and the corresponding brief description.
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Table A.1: Haralick features and formulas
Textural Features Formula
Energy f1 =
P
i
P
j{p(i, j)}2
Contrast f2 =
PNg 1
n=0 n
2
 PNg
i=1
PNg
j=1 p(i, j)||i  j| = n
 
Correlation f3 =
P
i
P
j(ij)p(i,j) µxµy
 x y
Sum of squares: variance f4 =
P
i
P
j(i  µ)2p(i, j)
Inverse di↵erence moment (local homogeneity) f5 =
P
i
P
j
1
1+(i j)2p(i, j)
Sum average f6 =
P2Ng
i=2 ipx+y(i)
Sum variance f7 =
P2Ng
i=2 (i  f8)2px+y(i)
Sum entropy f8 =  
P2Ng
i=2 px+y(i)log{px+y(i)}
Entropy f9 =  
P
i
P
j p(i, j)log{p(i, j)}
Di↵erence variance f10 =variance of px y
Di↵erence entropy f11 =  
PNg 1
i=0 px y(i)log{px y(i)}
Cluster shade f12 =
PNg 1
i=0
PNg 1
j=0 {i+ j   µx   µy}3p(i, j)
Cluster prominence f13 =
PNg 1
i=0
PNg 1
j=0 {i+ j   µx   µy}4p(i, j)
* Ng denotes the number of distinct grey levels used; µx,µy, x and  y are the means and standard
deviations of the partial probability density px and py; px(i) =
PNg
j=1 p(i, j), py(j) =
PNg
i=1 p(i, j);
px+y(k) =
PNg 1
i=0
PNg 1
j=0 p(i, j), i+ j = k and k = 2, 3, ..., 2Ng; px y(k) =
PNg 1
i=0
PNg 1
j=0 p(i, j), |i 
j| = k and k = 0, 1, ..., Ng   1.
Table A.2: Histogram Features and formulas
Histogram Features Formula
Mean m =
PL 1
i=0 zip(zi)
Uniformity U =
PL 1
i=0 p
2(zi)
Entropy e =  PL 1i=0 p(zi)logp(zi)2
* zi denotes a random variable indicating intensity,
p(zi) is the histogram of the the intensity values
within ragion of interest (ROI), and L is the number
of possible intensity levels.
The 972 preprocessed RFs are highly correlated when checking for Pearson
correlation. Figure A.1 clearly shows that the RFs are highly correlated with the
block structure due to two imaging modalities as well as two major normalizing
approaches (ratio-1 and ratio-2) applied during feature extraction.
In our analysis, we chose to apply dimensional reduction approaches to our RFs. The
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Table A.3: RF groups and description
RF group name Description
F Region
Regional features including tumor area, maximum intensity,
minimum intensity, mean intensity of T2-weighted FLAIR image
F LoG Tex R1
Ratio1(filter/unfiltered) Haralick texture features derived from
LoG filtered T2-weighted FLAIR image
F Unft Hist Histogram features derived from unfiltered T2-weighted FLAIR image
F LoG Hist R1
Ratio1(filter/unfiltered) histogram features derived from LoG filtered
T2-weighted FLAIR image
T1 Region
region features including tumor area, maximum intensity,
minimum intensity, mean intensity of T1-post contrast image
T1 LoG Tex R1
Ratio1(filter/unfiltered) Haralick texture features derived from
LoG filtered T1-post contrast image
T1 Unft Hist Histogram features of unfiltered T1-post contrast image
T1 LoG Hist R1
Ratio1(filter/unfiltered) histogram features of LoG filtered T1-post
contrast image
F LoG Tex Fine
Haralick features derived from LoG filtered FLAIR image with
fine scale
F LoG Tex R2
Ratio2(coarse/fine) haralick features derived from LoG
filtered T2-weighted FLAIR image
F LoG Hist Fine Histogram features of fine LoG filtered T2-weighted FLAIR image
F LoG Hist R2
Ratio2(coarse/fine) histogram features of LoG filtered
T2-weighted FLAIR image
F Gauss Hist Fine
Histogram features of Gaussian filtered FLAIR image
with fine scale
F Gauss Hist R2
Ratio2(coarse/fine) histogram features derived from Gaussian
filtered T2-weighted FLAIR image
T1 LoG Tex Fine
Haralick features derived from LoG filtered T1-post contrast
image with fine scale
T1 LoG Tex R2
Ratio2(coarse/fine) haralick texture features derived from
Gaussian filtered T2-weighted FLAIR image
T1 LoG Hist Fine
Histogram features of LoG filtered T1-post contrast
image with fine scale
T1 LoG Hist R2
Ratio2(coarse/fine) histogram features derived from
LoG filtered T1-post contrast image
T1 Gauss Hist Fine
Histogram features of Gaussian filtered T1-post
contrast image with fine scale
T1 Gauss Hist R2
Ratio2(coarse/fine) histogram features derived from Gaussian
filtered T1-post contrast image
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Figure A.1: Heatmap of the Pearson correlation among radiomic features (972 features)
typical technique is principal component analysis (PCA), however, the key limitation
lies in that it does not lead to sparse loadings, making it harder to interpret the
results. Hence, alternatively, the sparse PCA algorithm developed by [125] was
applied with the formulation described below.
Suppose Zi is the ith principal component derived from ordinary PCA of ma-
trix X with n samples and p predictors, where the loading matrix is denoted as Vi.
By regressing PC on X with penalization, sparse loading can be achieved.
 ˆ = arg min||Zi  X ||2 +  || ||2 +  1|| ||1
where || ||1 =
Pp
j=1 | j|. The updated sparse loading can be expressed as Vˆi =  ˆ|| ˆ|| ,
and XVˆi is the ith approximated principal component. For a more detailed theorem
and proof, see the appendix for the publication by Zou and Hastie (2006).
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The loadings as well as the leading principal components were derived from both
ordinary PCA and sparse PCA, based on RF-prespecified groups, the squared loading
proportion of the principal analysis is calculated respectively. This information is
shown in Figure A.2 below and in Figure 2.2 in the main text. When comparing
these two heatmaps, we can explicitly see a great di↵erence in the sparsity level. We
utilized 22 leading principal components derived from sparse PCA as our imaging
features in modeling stage II and stage III. We call them “radiomic-meta features”
(RmFs) in the analysis.
Figure A.2: PCA Squared loadings proportion for each RF group. For each of the 23 PC
scores, the sum of the squared loadings of each group is calculated after dividing by the
total sum of the squared loadings that equals exactly 1. The heatmap shows this values in
grey level, interpreted the RF group importance for each PC component. The grey level
ranging from white to black matches the proportional values ranging from 0 to 1.
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A.2.3 Dataset Sample Size
Figure A.3 shows the diagram of the sample size description of genomic data of
di↵erent platform, radiomic data sample size and the clinical data sample size as well
as their intersection sample sizes.
mRNA: continuous data
CN: log transformed continuous data
microRNA: continuous data
Radiomic data: continuous
Clinical: continuous data (we took the survival in month with log2 transformation
as the outcomes)
mRNA		
(N=558)	
microRNA	
(N=575)	
CN	
	(N=308)	
		308	 		529	
			304	
304	
Genomics	
(N=304)	
Clinical	
(N=596)	
Radiomics	
(N=82)	
		78	
		304	
		82	
		78	
Figure A.3: Diagram of sample size, there are 304 samples having all mRNA, CN and
microRNA information, and 78 samples have clinical and Radiomic information.
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A.2.4 Missing value imputation for genomic platform data
We have missing values in the copy number data set, with 4.3% of the data missing.
To impute the missing values, we chose to use the following steps. First, we impute
each NA with the average values of the other patients (mean imputation). Second,
using the complete matrix with mean imputation to calculate the correlation matrix
between markers, for each target marker with missing elements, we select 3 markers
that are the most highly positively correlated with this marker. Third, we regress
the target marker on the 3 selected markers and obtain the predicted values. Lastly,
we replace the predicted values for the missing elements of the target marker in the
original matrix.
A.3 Nonlinearity Checking for Genomic Model
We applied generalized additive model (GAM) in Genomic Model for each gene given
that GAM, compared with General Linear Model (GLM), can achieve higher flexi-
bility in modeling the genomic mechanisms. To check the existence of nonlinearity,
we show the comparison of GLM and GAM in terms of ANOVA p-values for model
comparison across all 49 genes. Moreover, we also show the fitted smooth curves
and the corresponding confidence interval lines for several genes and the platforms in
below.
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Figure A.4: Histogram of ANOVA p-value when doing model comparison (GLM vs. GAM
and GLM is nested into GAM), small p-value indicates the two models have significant
di↵erence and GAM is preferred over GLM.
Figure A.5: Fitted smoothing curve for the 1st leading PC score of copy number alteration
of gene AKT1, the figure shows the existence of nonlinearity
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Figure A.6: Fitted smoothing curve for the 2st leading PC score of copy number alteration
of gene AKT1, the figure shows the existence of nonlinearity
Figure A.7: Fitted smoothing curve for the 1st leading PC score of microRNA mapped
with gene MET, the figure shows the existence of nonlinearity
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A.4 Additional Results
A.4.1 Magnitude in Stage II
In the radiogenomic model, we dig into the relationship between the multiplatform
genomic data and RmFs; the magnitudes (posterior mean of the coe cients) are
shown in Figure A.8.
Figure A.8: Posterior mean of magnitude from stage II (radiogenomic model).
For each RmF, the posterior mean of  jg is the magnitude of the gth’s mRNA part explained
by the jth genomic platform. After filtering, 92 gene-platform combinations are sorted and
grouped by gene, and the positive and negative e↵ects are respectively illustrated in red
and purple.
A.4.2 Convergence Checking
We applied Bayesian Normal Gamma shrinkage model taking account of the multi-
scale datasets in both stage II and stage III, thus, we check the convergence here for
the parameters and hyperparameters in stage II and stage III.
In stage III, we have totally 185 parameters including  ji,  ji and j = 1, 2, 3, 4; i =
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1, 2, 3, ..., 22,  2,  j (j = 1, 2, 3, 4) and 1/ 2j (j = 1, 2, 3, 4). We ran MCMC for 30000
iterations and summarize the results using 20000 samples with the burn-in samples
removed. We evaluate the convergence by checking traceplots of 3 main parameter
vectors:  s,  s and  2, as well as the ratio of  j/(1/ 2j ) which identifiably leads to
the estimation of  s.
In addition, we check the convergence of the parameters in Stage III using Geweke
test [30] where we test for the mean di↵erence between first 10% proportion and the
last 50% of the samples for all the parameters. P values are illustrated via histogram
plots as in the following figures. The histogram is not skewed to the right which
indicates proper mixing for MCMC iterations. In all, our result summary is based
on the chains which are long enough to guarantee the convergence.
Figure A.9: Geweke test for all parameters, 7.7% have p value smaller than 0.05.
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A.5 Sensitivity Analysis
Based on the prior settings described in the paper, for stage III, I = {ICN ,ImiR,IO,Ig¯},
and the e↵ect parameter ↵ = {↵1,↵2,↵3,↵4}, then the model and prior construction
can be expressed as
Y = I↵+ ✏
Y ⇠ Normal(I↵,  2INGIC)
↵ ⇠ Normal(0, D )
D = diag( 1,1, 1,2, ..., 1,K , 2,1, 2,2, ..., 2,K , ..., J,1, J,2, ..., J,K),
where J denotes the total number of di↵erent RF combination types (j = 1, 2, 3, ..., J ,
our J = 4), k denotes the RF index (k = 1, 2, 3, ..., K). Further, we as-
sign our prior and hyper-prior distributions as  j,k ⇠ Gamma( j, 1/(2 2j )),
 2 ⇠ InverseGamma(u1, u2),  j ⇠ exp(d), and 1/(2 2j ) ⇠ Gamma(e˜, f˜/(2 j)).
We have hyperparameters d, e˜ and f˜ . For hyperparameter f˜ , it is suggested
that f˜ comes from minimum-length least squares (MLLS) of the coe cients. Thus,
we do the sensitivity analysis by adjusting d, e˜. In our analysis, we set up d = 1 and
e˜ = 2, in the sensitivity analysis, we set up d = 0.5, 2 and e˜ = 1, 4 respectively.
Results in below show that the selected RmF components are almost the same
across di↵erent hyperparameter settings. Even for some of the features which are
not selected given lower value of d, they are close to the margin. Thus, our model
is consistent with the hyperparameter settings. Since we applied the same prior for
stage II, similar results will be drawn.
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(a) positively significant RmF combinations (b) negatively significant RmF combinations
Figure A.10: Results of Stage III when d = 0.5
(a) positively significant RmF combinations (b) negatively significant RmF combinations
Figure A.11: Results of Stage III when d = 2
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(a) positively significant RmF combinations (b) negatively significant RmF combinations
Figure A.12: Results of Stage III when e˜ = 1
(a) positively significant RmF combinations (b) negatively significant RmF combinations
Figure A.13: Results of Stage III when e˜ = 4
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Appendix B
BLINK Implementation Details
B.1 MCMC SAMPLING
B.1.1 Updating  k and  k
In our analysis, we have K regressions, for simplicity, we take one as the example,
considering the kth regression:
Yk = Xk k + ✏k, ✏k ⇠ N (0,  2kI) (B.1)
Note that the response vector has been centered and the predictor matrix is stan-
dardized, so as to avoid intercept and to obtain more interpretable results especially
for coe cients. Given the prior described in equation (2) and (3), with the updated
prior inclusion probability respectively for each predictor derived from equation (6),
for simplicity, we denote it as p( kj = 1) = ⇡kj. The MCMC estimation of the
parameter set ( k, k,  2k) can be implemented using Gibbs sampling:
• sample each  kj from p( kj) = (1  ⇡kj)p( kj; 0, c 2k) 0 + ⇡kjp( kj; 0, c 2k)I kj=1
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• sample  k from N ((X 0X/ 2k+D 1) 1X 0y/ 2k, (X 0X/ 2k+D 1) 1) andD =
diag( 2k kj)
• update ⇡kj based on equation (6) which involves other updated parameters.
B.1.2 Updating ✓km and ⌧km
The ✓km and ⌧km are sampled from their joint posterior conditional distribution.
Considering the terms that only contain these two parameters from equation (2), the
posterior full conditional of ✓km and ⌧km can be formulated as:
✓km, ⌧km|rest
/
pY
j=1
{Ck(⌫j,⇥) 1exp(2✓km kj mj)}w⌧km(1  w)1 ⌧km [(1  ⌧km) 0
+ ⌧km
 ↵✓✓
 (↵✓)
✓↵✓ 1km e
  ✓✓km ]
(B.2)
Considering the fact that the normalizing constant is not analytically tractable, we
apply Metropolis-Hastings method to sample ✓km and ⌧km. The MCMC sampling
scheme in this step involves the approach described by Gottardo and Raftery (cite),
which for each iteration, the entire step involves two steps, between-model move and
within-model move. This approach is also called reversible jump Markov chain Monte
Carlo (RJMCMC). Following shows the specific algorithm:
• between-model move
- If the ⌧km = 1 in the current state, we take ⌧ ⇤km = 0 and ✓
⇤
km = 0 as our
proposed sample pairs.
- If the ⌧km = 0 in the current state, we propose ⌧ ⇤km = 1 and ✓
⇤
km from the
proposal distribution, we chose to set up the proposal distribution as f(✓⇤km) =
Gamma(↵⇤✓,  
⇤
✓ ). The MH ratio given the posterior and proposal distributions
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when moving from ⌧km = 1 to ⌧km = 0 can be written as
R1!0 =
p(✓⇤km, ⌧
⇤
km|rest)/f(✓⇤km)
p(✓km, ⌧km|rest)/f(✓km)
=
1  w
w
·  (↵✓)( 
⇤
✓ )
↵⇤✓
 (↵⇤✓)( 
⇤
✓ )
↵✓
(✓km)
↵⇤✓ , ↵✓
· exp{( ✓    ⇤✓ )✓km} ·
PY
j=1
Ck(⌫j,⇥) · exp( 2✓km kj mj)
Ck(⌫j,⇥⇤)
(B.3)
Where ⇥⇤ denotes the updated ⇥ with element ✓km replaced by ✓⇤km.
When moving from ⌧km = 0 to ⌧km = 1, the ratio can be expressed as
R0!1 =
p(✓⇤km, ⌧
⇤
km|rest)/f(✓⇤km)
p(✓km, ⌧km|rest)/f(✓km)
=
w
1  w ·
 (↵⇤✓)( ✓)
↵✓
 (↵✓)( ⇤✓ )
↵⇤✓
(✓⇤km)
↵✓, ↵⇤✓
· exp{( ⇤✓    ✓)✓⇤km} ·
PY
j=1
Ck(⌫j,⇥) · exp(2✓⇤km kj mj)
Ck(⌫j,⇥⇤)
(B.4)
• within-model move
When ⌧km sampled from the between-model move euqals 1, we propose within-
model move. That is, we propose another ✓⇤km from the same proposal distribu-
tion and compute the MH ratio as
R0!1 =
p(✓⇤km, ⌧
⇤
km|rest)/f(✓⇤km)
p(✓km, ⌧km|rest)/f(✓km)
=
 ✓⇤km
✓km
 ↵✓ ↵⇤✓ · exp{( ⇤✓    ✓)(✓⇤km   ✓km)} · PY
j=1
Ck(⌫j,⇥)exp(2(✓⇤km   ✓km) kj mj)
Ck(⌫j,⇥⇤)
(B.5)
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B.1.3 Updating ⌫j
Given the prior of ⌫j, the prosterior distribution is derived as
⌫j|rest / exp(⌫j(a+ 1
T j))
C(⌫j,⇥)(1 + e⌫j)a+b
(B.6)
Similarly, the normalizing constant is not analytical tractable, we apply MH approach
in this step as well. For each j, we propose q⇤ from proposal density, here we apply
the same distribution, Beta(a⇤, b⇤) distribution, and our new ⌫j can be calculated
from ⌫⇤j = logit(q
⇤). The MH ratio can be expressed as
R⌫ =
p(⌫⇤j |rest)q(⌫j)
p(⌫j|rest)q(⌫⇤j )
=
Ck(⌫j,⇥)
Ck(⌫⇤j ,⇥)
· exp((⌫
⇤
j   ⌫j)(1T j + a  a⇤)) · (1 + exp(⌫j))a+b a⇤ b⇤
(1 + exp(⌫⇤j ))a+b a
⇤ b⇤
(B.7)
B.2 Table of pathway gene membership and sam-
ple size information
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Pathway Genes
Apoptosis BAK1 BAX BID BCL2L11 CASP7 BAD
BCL2 BCL2L1 BIRC2
Breast reactive CAV1 MYH11 RAB11A RAB11B CTNNB1 GAPDH
RBM15
Cell cycle CDK1 CCNB1 CCNE1 CCNE2 CDKN1B PCNA
FOXM1
Core reactive CAV1 CTNNB1 RBM15 CDH1 CLDN7
DNA damage response TP53BP1 ATM BRCA2 CHEK1 CHEK2 XRCC5
MRE11A TP53 RAD50 RAD51 XRCC1
EMT FN1 CDH2 COL6A1 CLDN7 CDH1 CTNNB1
SERPINE1
PI3K/AKT AKT1 AKT2 AKT3 GSK3A GSK3B CDKN1B
AKT1S1 TSC2 INPP4B PTEN
RAS/MAPK ARAF JUN RAF1 MAPK8 MAPK1 MAPK3
MAP2K1 MAPK14 RPS6KA1 YBX1
RTK EGFR ERBB2 ERBB3 SHC1 SRC
TSC/mTOR EIF4EBP1 RPS6KB1 MTOR RPS6 RB1
Hormone receptor ESR1 PGR AR
Hormone signaling (Breast) INPP4B GATA3 BCL2
Table B.1: Pathway-Gene membership Table
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bar rppa bar mRNA bar cna bar methy bar miRNA bar inter
ACC 46 79 90 80 80 45
BLCA 344 408 408 412 409 334
BRCA 869 1095 1080 785 756 498
CESC 171 304 295 307 307 160
CHOL 30 36 36 36 36 30
COAD 354 285 451 296 221 186
DLBC 33 48 48 48 47 33
ESCA 126 184 184 185 184 124
GBM 204 161 577 141 565 31
HNSC 346 520 522 528 486 304
KICH 63 66 66 66 66 63
KIRC 445 533 528 319 254 139
KIRP 207 290 288 275 291 203
LGG 423 516 513 516 512 416
LIHC 184 371 370 377 372 171
LUAD 362 515 516 458 450 309
LUSC 325 501 501 370 342 233
MESO 61 87 87 87 87 61
OV 402 305 582 10 475 0
PAAD 105 178 184 184 178 97
PCPG 79 179 162 179 179 77
PRAD 351 497 494 498 494 342
READ 129 94 165 98 90 68
SARC 218 259 257 261 259 211
SKCM 351 468 469 469 448 333
STAD 392 415 441 395 389 291
TGCT 114 150 150 150 150 114
THCA 368 505 502 507 506 362
THYM 90 120 123 124 124 87
UCEC 404 177 539 431 411 101
UCS 48 57 56 57 56 46
UVM 12 80 80 80 80 12
Table B.2: Number of the samples for each platform for pan-cancer; rppa is proteomic
data, mRNA is gene expression, cna is copynumber alteration, methy is methylation,
miRNA is microRNA, inter is the intersection of all platforms
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